
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Cytokine release syndrome in solid tumors - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="152519D28AEEC7830519D2000E82BBDA.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cancer">
<meta name="citation_title" content="Cytokine release syndrome in solid tumors">
<meta name="citation_author" content="David Synnott">
<meta name="citation_author_institution" content="Beaumont Hospital, Dublin, Ireland">
<meta name="citation_author_institution" content="Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland">
<meta name="citation_author_institution" content="Beaumont RCSI Cancer Centre, Dublin, Ireland">
<meta name="citation_author" content="David O’Reilly">
<meta name="citation_author_institution" content="Beaumont Hospital, Dublin, Ireland">
<meta name="citation_author_institution" content="Beaumont RCSI Cancer Centre, Dublin, Ireland">
<meta name="citation_author_institution" content="RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland">
<meta name="citation_author" content="Declan De Freitas">
<meta name="citation_author_institution" content="Beaumont Hospital, Dublin, Ireland">
<meta name="citation_author_institution" content="Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland">
<meta name="citation_author_institution" content="RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland">
<meta name="citation_author" content="Jarushka Naidoo">
<meta name="citation_author_institution" content="Beaumont Hospital, Dublin, Ireland">
<meta name="citation_author_institution" content="Beaumont RCSI Cancer Centre, Dublin, Ireland">
<meta name="citation_author_institution" content="RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="131">
<meta name="citation_issue" content="17">
<meta name="citation_firstpage" content="e70069">
<meta name="citation_doi" content="10.1002/cncr.70069">
<meta name="citation_pmid" content="40847830">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/pdf/CNCR-131-e70069.pdf">
<meta name="description" content="Cytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has ...">
<meta name="og:title" content="Cytokine release syndrome in solid tumors">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Cytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374489">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/cncr.70069"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/CNCR-131-e70069.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374489%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374489/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374489/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/cncr.70069" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cancer</button></div>. 2025 Aug 23;131(17):e70069. doi: <a href="https://doi.org/10.1002/cncr.70069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/cncr.70069</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Cytokine release syndrome in solid tumors</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Synnott%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">David Synnott</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">David Synnott</span>, <span class="degrees">MB, BCh</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Beaumont Hospital, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Beaumont RCSI Cancer Centre, Dublin, Ireland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Synnott%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">David Synnott</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22O%E2%80%99Reilly%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">David O’Reilly</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">David O’Reilly</span>, <span class="degrees">MB, BCh</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Beaumont Hospital, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Beaumont RCSI Cancer Centre, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>4</sup>
</sup>RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22O%E2%80%99Reilly%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">David O’Reilly</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Freitas%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Declan De Freitas</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Declan De Freitas</span>, <span class="degrees">MB, BCh, PhD</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Beaumont Hospital, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>4</sup>
</sup>RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Freitas%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Declan De Freitas</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Naidoo%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jarushka Naidoo</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Jarushka Naidoo</span>, <span class="degrees">MB, BCh, MHS</span>
</h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Beaumont Hospital, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Beaumont RCSI Cancer Centre, Dublin, Ireland</div>
<div class="p">
<sup>
<sup>4</sup>
</sup>RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Naidoo%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jarushka Naidoo</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>4</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="cncr70069-aff-0001">
<sup>
<sup>1</sup>
</sup>Beaumont Hospital, Dublin, Ireland</div>
<div id="cncr70069-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland</div>
<div id="cncr70069-aff-0003">
<sup>
<sup>3</sup>
</sup>Beaumont RCSI Cancer Centre, Dublin, Ireland</div>
<div id="cncr70069-aff-0004">
<sup>
<sup>4</sup>
</sup>RCSI University of Health Sciences, RCSI Cancer Centre, Dublin, Ireland</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence</strong>
, 
David Synnott, Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland. 
Email: <span>davidsynnott13@gmail.com</span>

</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 10; Received 2025 Jan 31; Accepted 2025 Jul 21; Issue date 2025 Sep 1.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Cancer</em> published by Wiley Periodicals LLC on behalf of American Cancer Society.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374489  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40847830/" class="usa-link">40847830</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Cytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a growing need to address CRS in the context of solid organ tumors due to differences in tumor microenvironment, immunotherapy indications, and patient population. This review aims to provide an overview of CRS in solid tumors, outlining its pathophysiology, clinical presentation, and current management strategies. The complexities of CRS in solid tumors arise from challenges such as the immunosuppressive nature of the tumor microenvironment and the overlap of tumor‐associated antigens with healthy tissues, potentially increasing the risk of severe on‐target off‐tumor toxicities. The review emphasizes early detection and grading of CRS as essential for patient safety and effective intervention. Management of CRS involves supportive care for mild cases, whereas severe presentations often require targeted therapies like tocilizumab, corticosteroids, and escalation to the intensive care unit for organ support. The decision to rechallenge or withhold immunotherapy requires careful consideration of patient‐specific goals and risks. Emerging treatments such as other cytokine inhibitors, plasma exchange, and suicide gene systems are promising avenues for mitigating severe CRS. Future research focuses on refining risk stratification tools, novel therapeutic agents, and evaluating long‐term outcomes. A deeper understanding of CRS in solid tumors will enable more personalized treatment approaches, enhancing the safety and efficacy of immunotherapies for this patient population.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> adoptive, chimeric antigen receptor therapy, cytokine release syndrome, drug‐related side effects and adverse reactions, immune checkpoint inhibitors, immunotherapy, solid tumors</p></section></section><section class="abstract" id="abstract2"><h2>Short abstract</h2>
<p>The tumor microenvironment alters cytokine kinetics, making cytokine release syndrome in solid organ tumors distinct from hematologic disease. This review distils current evidence on pathophysiology, grading, interleukin‐6–centered therapy, and patient‐specific decisions regarding management.</p></section><section id="cncr70069-sec-0010"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Over the past decade, cancer immunotherapy has marked a major advance in cancer treatment. This has resulted in incremental improvements in outcomes for patients, particularly in melanoma, lung cancer, renal cell cancer and others.<a href="#cncr70069-bib-0001" class="usa-link" aria-describedby="cncr70069-bib-0001">
<sup>1</sup>
</a>, <a href="#cncr70069-bib-0002" class="usa-link" aria-describedby="cncr70069-bib-0002">
<sup>2</sup>
</a>, <a href="#cncr70069-bib-0003" class="usa-link" aria-describedby="cncr70069-bib-0003">
<sup>3</sup>
</a> Therapies like immune checkpoint inhibitors (ICIs), bispecific T‐cell engaging antibodies (BiTEs), and adoptive cell therapies (ACT), including chimeric antigen receptor (CAR) T‐cells, exemplify this progress. To date, there are few licensed immunotherapeutic strategies for solid organ tumors outside ICIs (see Table <a href="#cncr70069-tbl-0001" class="usa-link">1</a>), however, there is emerging evidence for the utility of BiTEs in small cell lung carcinoma<a href="#cncr70069-bib-0004" class="usa-link" aria-describedby="cncr70069-bib-0004">
<sup>4</sup>
</a> and uveal melanoma.<a href="#cncr70069-bib-0005" class="usa-link" aria-describedby="cncr70069-bib-0005">
<sup>5</sup>
</a> CAR T‐cell therapy is not yet approved for solid organ tumors, but stage III clinical trials are ongoing (Table <a href="#cncr70069-tbl-0001" class="usa-link">1</a>).<a href="#cncr70069-bib-0007" class="usa-link" aria-describedby="cncr70069-bib-0007">
<sup>7</sup>
</a> Despite their clinical success, these therapies can lead to significant toxicities, often driven by immune activation.</p>
<section class="tw xbox font-sm" id="cncr70069-tbl-0001"><h3 class="obj_head">TABLE 1.</h3>
<div class="caption p"><p>FDA approvals and emerging indications of immunotherapy for solid organ malignancies associated with the development of CRS.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000"><th colspan="5" align="left" valign="bottom" rowspan="1">FDA‐approved agents</th></tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Class</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Drugs</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Diseases</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Incidence of CRS (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Emerging indications</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">PD‐1/PD‐L1 inhibitors (ICI)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab</td>
<td align="left" valign="top" rowspan="1" colspan="1">Melanoma, HCC, NSCLC, esophageal, colorectal, gastric, RCC, bladder, breast, cervical</td>
<td align="left" valign="top" rowspan="1" colspan="1">1</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">LAG‐3 (ICI)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Relatlimab</td>
<td align="left" valign="top" rowspan="1" colspan="1">Melanoma</td>
<td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
<td align="left" valign="top" rowspan="1" colspan="1">Non–small cell lung cancer, colorectal cancer, urothelial cancer, soft tissue sarcoma, Merkel cell carcinoma</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CTLA‐4 Inhibitors (ICI)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Ipilimumab, tremilimumab</td>
<td align="left" valign="top" rowspan="1" colspan="1">Melanoma, HCC, NSCLC, esophageal, colorectal, gastric, RCC</td>
<td align="left" valign="top" rowspan="1" colspan="1">1</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">DLL‐3 (BiTE)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Tarlatamab<a href="#cncr70069-bib-0004" class="usa-link" aria-describedby="cncr70069-bib-0004">
<sup>4</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Extensive stage small cell lung cancer</td>
<td align="left" valign="top" rowspan="1" colspan="1">51</td>
<td align="left" valign="top" rowspan="1" colspan="1">Limited stage small cell lung cancer</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">T‐cell receptor gp100 specific (BiTE)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Tebentafusp<a href="#cncr70069-bib-0005" class="usa-link" aria-describedby="cncr70069-bib-0005">
<sup>5</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Uveal melanoma</td>
<td align="left" valign="top" rowspan="1" colspan="1">89</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cutaneous melanoma</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dendritic‐cell vaccine</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sipuleucel T<a href="#cncr70069-bib-0006" class="usa-link" aria-describedby="cncr70069-bib-0006">
<sup>6</sup>
</a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">mCRPC</td>
<td align="left" valign="top" rowspan="1" colspan="1">3.5–71.2</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Phase 3 studies investigating CAR T in solid tumors</th></tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Class</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Drugs</th>
<th style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1" colspan="1">Diseases</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Incidence of CRS (%)</th>
<th align="left" valign="bottom" rowspan="1" colspan="1">Clinicaltrials.gov<a href="#cncr70069-bib-0007" class="usa-link" aria-describedby="cncr70069-bib-0007">
<sup>7</sup>
</a>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CAR T cells</td>
<td align="left" valign="top" rowspan="1" colspan="1">Anti CEA CAR T cells</td>
<td align="left" valign="top" rowspan="1" colspan="1">Pancreatic cancer</td>
<td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
<td align="left" valign="top" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04037241" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04037241</a></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">IL‐15 receptor agonist</td>
<td align="left" valign="top" rowspan="1" colspan="1">N‐803</td>
<td align="left" valign="top" rowspan="1" colspan="1">NSCLC, nonmuscle–invasive bladder cancer</td>
<td align="left" valign="top" rowspan="1" colspan="1">90</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<a href="https://clinicaltrials.gov/ct2/show/NCT03022825" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03022825</a>; <a href="https://clinicaltrials.gov/ct2/show/NCT03520686" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03520686</a>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70069-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="cncr70069-note-0001"><p>Abbreviations: CAR, chimeric antigen receptor; CRS, cytokine release syndrome; CTLA‐4, cytotoxic T lymphocyte antigen‐4; DLL3, delta‐like canonical Notch ligand 3; FDA, Food and Drug Administration; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; IL, interleukin; LAG‐3, lymphocyte activation gene 3; mCRPC, Metastatic castration‐resistant prostate cancer; NSCLC, non–small cell lung cancer; PD‐L1, programmed death‐ligand 1; RCC, renal cell carcinoma.</p></div></div></section><p>Cytokine release syndrome (CRS) is a potentially life‐threatening complication, occurring more commonly in patients receiving CAR T‐cell therapy and BiTEs. CRS can present as a spectrum from mild to severe, with worsening symptoms such as fever, hypotension, and hypoxia.<a href="#cncr70069-bib-0008" class="usa-link" aria-describedby="cncr70069-bib-0008">
<sup>8</sup>
</a> It is a systemic inflammatory response triggered by an excessive immune reaction involving T cells, B cells, natural killer (NK) cells, and macrophages.<a href="#cncr70069-bib-0009" class="usa-link" aria-describedby="cncr70069-bib-0009">
<sup>9</sup>
</a> Early recognition and intervention of CRS is crucial to ensure appropriate diagnosis, management, and escalation of care. In the most severe cases, life‐threatening complications such as hypotension, requiring high‐dose vasopressors, and hypoxia, necessitating mechanical ventilation, can arise. Additionally, common laboratory abnormalities in CRS patients include cytopenias, coagulopathies, elevated liver enzymes, and acute kidney injury.<a href="#cncr70069-bib-0010" class="usa-link" aria-describedby="cncr70069-bib-0010">
<sup>10</sup>
</a>
</p>
<p>The incidence of CRS in patients receiving CAR T‐cell therapy has been reported to range from 57%–93%.<a href="#cncr70069-bib-0011" class="usa-link" aria-describedby="cncr70069-bib-0011">
<sup>11</sup>
</a> Although CAR T‐cell therapy is predominantly used in hematological malignancies, clinical trials are currently ongoing to investigate efficacy in solid organ tumors.<a href="#cncr70069-bib-0012" class="usa-link" aria-describedby="cncr70069-bib-0012">
<sup>12</sup>
</a> Case reports have also described CRS occurrence in ICIs, which are commonly used in solid organ malignancies, albeit a less frequent and often underreported adverse effect.<a href="#cncr70069-bib-0013" class="usa-link" aria-describedby="cncr70069-bib-0013">
<sup>13</sup>
</a>, <a href="#cncr70069-bib-0014" class="usa-link" aria-describedby="cncr70069-bib-0014">
<sup>14</sup>
</a> Recent phase 2 and phase 3 clinical trials of newer BiTEs having an incidence as high as 51% and 89%.<a href="#cncr70069-bib-0004" class="usa-link" aria-describedby="cncr70069-bib-0004">
<sup>4</sup>
</a>, <a href="#cncr70069-bib-0015" class="usa-link" aria-describedby="cncr70069-bib-0015">
<sup>15</sup>
</a>
</p>
<p>Although CRS and its management have been extensively characterized in hematological malignancies, evidence relating to CRS in solid tumors remains scarce. This article explores possible mechanistic and clinical factors that may render CRS in solid tumors analogous or distinct from hematological cases, in anticipation of its expected increase in incidence. Moreover, solid tumors exhibit diverse stromal architectures, vascular perfusion patterns, and tumor‐immune microenvironments that may alter cytokine kinetics and symptom manifestation. Accordingly, this review systematically probes this emerging challenge by organizing the discussion into four principal aims:</p>
<ol class="list" style="list-style-type:decimal">
<li><p>Explore the pathophysiology of CRS in solid organ tumors.</p></li>
<li><p>Discuss the clinical presentation and grading of CRS.</p></li>
<li><p>Discuss the management of CRS with emphasis on solid organ tumors.</p></li>
<li><p>Explore the challenges of treating CRS in solid organ tumors and the potential future directions of therapy.</p></li>
</ol></section><section id="cncr70069-sec-0020"><h2 class="pmc_sec_title">PATHOPHYSIOLOGY OF CRS</h2>
<p>Cytokines are small‐molecule signaling proteins that regulate immune responses, hematopoiesis, and communication between cells. They also mediate host responses to infections, inflammatory stimuli, and medications.<a href="#cncr70069-bib-0016" class="usa-link" aria-describedby="cncr70069-bib-0016">
<sup>16</sup>
</a>, <a href="#cncr70069-bib-0017" class="usa-link" aria-describedby="cncr70069-bib-0017">
<sup>17</sup>
</a>, <a href="#cncr70069-bib-0018" class="usa-link" aria-describedby="cncr70069-bib-0018">
<sup>18</sup>
</a> CRS was first described in the early 1990s as a complication of the anti–T‐cell antibody, muromonab‐CD3 (OKT3), which was used as an immunotherapy for solid organ transplantation.<a href="#cncr70069-bib-0019" class="usa-link" aria-describedby="cncr70069-bib-0019">
<sup>19</sup>
</a>, <a href="#cncr70069-bib-0020" class="usa-link" aria-describedby="cncr70069-bib-0020">
<sup>20</sup>
</a> In renal allograft recipients, it was identified that self‐limited, massive cytokine release correlated with the known spontaneously reversible clinical syndrome of fever, headache, and gastrointestinal symptoms experienced with first dose of OKT3. Serum tumor necrosis factor (TNF), interferon‐γ (IFN‐γ), and interleukin (IL)‐2 were transiently elevated during the period of acute symptoms.<a href="#cncr70069-bib-0019" class="usa-link" aria-describedby="cncr70069-bib-0019">
<sup>19</sup>
</a> The rise in cytokines and clinical symptoms were mitigated in the patients who received concomitant corticosteroids, suggesting an explanation for this common side effect.</p>
<p>As immunotherapies have continued to develop and their use becomes more common, CRS has been described in several antibody‐based therapies such as nivolumab,<a href="#cncr70069-bib-0021" class="usa-link" aria-describedby="cncr70069-bib-0021">
<sup>21</sup>
</a> anti‐thymocyte globulin (ATG),<a href="#cncr70069-bib-0022" class="usa-link" aria-describedby="cncr70069-bib-0022">
<sup>22</sup>
</a> rituximab,<a href="#cncr70069-bib-0023" class="usa-link" aria-describedby="cncr70069-bib-0023">
<sup>23</sup>
</a> obinutuzumab,<a href="#cncr70069-bib-0024" class="usa-link" aria-describedby="cncr70069-bib-0024">
<sup>24</sup>
</a> alemtuzumab,<a href="#cncr70069-bib-0025" class="usa-link" aria-describedby="cncr70069-bib-0025">
<sup>25</sup>
</a> brentuximab,<a href="#cncr70069-bib-0026" class="usa-link" aria-describedby="cncr70069-bib-0026">
<sup>26</sup>
</a> and dacetuzumab.<a href="#cncr70069-bib-0027" class="usa-link" aria-describedby="cncr70069-bib-0027">
<sup>27</sup>
</a> Severe viral infections such as COVID‐19 or influenza can also trigger immune and nonimmune cell stimulation to the extent of CRS, sometimes referred to as a cytokine storm.<a href="#cncr70069-bib-0028" class="usa-link" aria-describedby="cncr70069-bib-0028">
<sup>28</sup>
</a>, <a href="#cncr70069-bib-0029" class="usa-link" aria-describedby="cncr70069-bib-0029">
<sup>29</sup>
</a>
</p>
<p>Although the precise mechanisms underlying CRS are still being investigated, it is widely understood that, based on data from hematological malignancies, the syndrome is initiated by the binding of BiTEs, CAR T cells, or less commonly ICIs, to their target antigens. The interaction not only activates the intended target cells but also induces activation in bystander immune and nonimmune cells.<a href="#cncr70069-bib-0010" class="usa-link" aria-describedby="cncr70069-bib-0010">
<sup>10</sup>
</a>, <a href="#cncr70069-bib-0011" class="usa-link" aria-describedby="cncr70069-bib-0011">
<sup>11</sup>
</a>, <a href="#cncr70069-bib-0030" class="usa-link" aria-describedby="cncr70069-bib-0030">
<sup>30</sup>
</a> This activation leads to the extensive release of various proinflammatory cytokines including IL‐6, IL‐1, IL‐5, IL‐10, IFN‐γ, TNF‐α, and transforming growth factors (TGFs) by B‐ and T‐lymphocytes and NK cells. CRS is further amplified through interactions with cellular bystanders, including endothelial cells, monocytes/macrophages, and dendritic cells, which escalate cytokine hypersecretion, worsen symptoms, and contribute to varying degrees of organ damage.<a href="#cncr70069-bib-0031" class="usa-link" aria-describedby="cncr70069-bib-0031">
<sup>31</sup>
</a> The key players implicated in the development of CRS include IFN‐γ, IL‐6, endothelial cells, and the tumor microenvironment (TME) in solid tumors.</p>
<p>NK centered platforms—tri‐specific killer engagers, CAR‐NK cells, and NK‐cell engagers—rarely provoke clinically relevant CRS in stark contrast to T‐cell redirecting CAR‐T, BiTE, or checkpoint inhibitors. To date, these data are based on hematological malignancies alone.<a href="#cncr70069-bib-0032" class="usa-link" aria-describedby="cncr70069-bib-0032">
<sup>32</sup>
</a>, <a href="#cncr70069-bib-0033" class="usa-link" aria-describedby="cncr70069-bib-0033">
<sup>33</sup>
</a> This is likely due to primary NK cells producing very little granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) or IL‐6 on engagement, so the macrophage amplification never starts.<a href="#cncr70069-bib-0034" class="usa-link" aria-describedby="cncr70069-bib-0034">
<sup>34</sup>
</a>
</p>
<section id="cncr70069-sec-0030"><h3 class="pmc_sec_title">IFN‐γ</h3>
<p>In the context of T‐cell engagers, CRS is activated by substantial release of IFN‐γ by either activated T cells or the tumor cells themselves, which can cause fever, neurological symptoms, and fatigue. The secreted IFN‐γ then triggers stimulation of other immune cells, notably macrophages.<a href="#cncr70069-bib-0035" class="usa-link" aria-describedby="cncr70069-bib-0035">
<sup>35</sup>
</a> This stimulation of macrophages leads to the production of cytokines such as IL‐6, TNF‐α, and IL‐10. IL‐6 appears to have the most prominent function in CRS and is consistently observed to be elevated in the serum of patients experiencing CRS.<sup>35–37</sup> This has been demonstrated in humanized mouse models where it was shown that human monocytes were a major source of IL‐1 and IL‐6 during CRS.<sup>36</sup> Translational research through in vitro assays and single‐cell RNA sequencing supports this, as well as the effectiveness of tocilizumab therapy, an IL‐6 receptor antagonist.<a href="#cncr70069-bib-0036" class="usa-link" aria-describedby="cncr70069-bib-0036">
<sup>36</sup>
</a>, <a href="#cncr70069-bib-0037" class="usa-link" aria-describedby="cncr70069-bib-0037">
<sup>37</sup>
</a>, <a href="#cncr70069-bib-0038" class="usa-link" aria-describedby="cncr70069-bib-0038">
<sup>38</sup>
</a>
</p></section><section id="cncr70069-sec-0040"><h3 class="pmc_sec_title">IL‐6</h3>
<p>IL‐6 is a pleiotropic cytokine with both proinflammatory and anti‐inflammatory properties. It is synthesized by a range of cell types, such as T cells, monocytes, macrophages, dendritic cells, mesenchymal cells, and osteoblasts. It plays various roles across different phases of inflammation, initially promoting tissue‐damaging inflammatory responses, subsequently aiding in the resolution of inflammation, and ultimately supporting tissue repair during the later stages.<a href="#cncr70069-bib-0039" class="usa-link" aria-describedby="cncr70069-bib-0039">
<sup>39</sup>
</a> IL‐6 can signal via two different pathways known as classical signaling and trans‐signaling. Classical IL‐6 signaling, which predominantly reduces inflammation, involves the binding of IL‐6 to membrane‐bound IL‐6 receptors (mIL‐6R) on the cell surface.<a href="#cncr70069-bib-0040" class="usa-link" aria-describedby="cncr70069-bib-0040">
<sup>40</sup>
</a> The mIL‐6R is not expressed on all cell types; its presence is predominantly limited to hepatocytes, plasma cells, megakaryocytes, and certain leucocytes such as neutrophils, monocytes, and T cells.<a href="#cncr70069-bib-0041" class="usa-link" aria-describedby="cncr70069-bib-0041">
<sup>41</sup>
</a> However, nearly all cells express gp130, a signal‐transducing component essential for IL‐6 signaling. Cells that only express gp130 can still be activated by IL‐6 through a mechanism known as trans‐signaling. In this process, IL‐6 binds to a soluble form of the IL‐6 receptor (sIL‐6R) in the extracellular environment. The resulting IL‐6/sIL‐6R complex can interact with gp130 on cells lacking mIL‐6R, initiating a proinflammatory signaling cascade seen in CRS.<a href="#cncr70069-bib-0040" class="usa-link" aria-describedby="cncr70069-bib-0040">
<sup>40</sup>
</a>, <a href="#cncr70069-bib-0042" class="usa-link" aria-describedby="cncr70069-bib-0042">
<sup>42</sup>
</a> IL‐6 plays a significant role in critical aspects of severe CRS that can lead to disseminated intravascular coagulation (DIC), including vascular leakage and the activation of both complement and coagulation pathways.<a href="#cncr70069-bib-0043" class="usa-link" aria-describedby="cncr70069-bib-0043">
<sup>43</sup>
</a> It is suggested that genetic variants in the IL‐6 gene can result in overexpression of IL‐6 via trans‐signaling and thus polymorphisms may predispose patients to CRS.<a href="#cncr70069-bib-0044" class="usa-link" aria-describedby="cncr70069-bib-0044">
<sup>44</sup>
</a>, <a href="#cncr70069-bib-0045" class="usa-link" aria-describedby="cncr70069-bib-0045">
<sup>45</sup>
</a> This is not yet in clinical use.</p></section><section id="cncr70069-sec-0050"><h3 class="pmc_sec_title">Endothelial cells</h3>
<p>Activation of endothelial cells is postulated to play a central role in the pathogenesis of severe CRS and potentially provide an explanation for the hallmarks of severe CRS such as capillary leakage, coagulopathy, and hypotension. Endothelial cells are the cells that line the interior surface of blood vessels, forming the thin layer of endothelium. The activation of endothelial cells can result in increased vascular permeability, facilitating the extravasation of plasma proteins and fluids into the interstitial space, which can contribute to hypotension and edema.<a href="#cncr70069-bib-0046" class="usa-link" aria-describedby="cncr70069-bib-0046">
<sup>46</sup>
</a> Markers of endothelial activation such as Ang‐2 and von Willebrand factor are frequently raised in the serum of patients with CRS and have been demonstrated to be an important source of IL‐6 in post‐mortem examination of fatal CRS.<a href="#cncr70069-bib-0047" class="usa-link" aria-describedby="cncr70069-bib-0047">
<sup>47</sup>
</a>, <a href="#cncr70069-bib-0048" class="usa-link" aria-describedby="cncr70069-bib-0048">
<sup>48</sup>
</a> IL‐6 trans‐signaling activates endothelial cells, which express gp130, causing production of additional inflammatory cytokines like IL‐6. The newly produced IL‐6 can further activate endothelial cells, both directly and through the generation of more sIL‐6R. This creates a positive feedback or proinflammatory loop, amplifying the CRS response and potentially leading to excessive inflammation and tissue damage.<a href="#cncr70069-bib-0049" class="usa-link" aria-describedby="cncr70069-bib-0049">
<sup>49</sup>
</a> The dysfunction of endothelial cells has been identified as a predictor of prognosis, CRS, and DIC in patients treated with anti‐CD19 CAR T cells.<a href="#cncr70069-bib-0050" class="usa-link" aria-describedby="cncr70069-bib-0050">
<sup>50</sup>
</a>
</p></section><section id="cncr70069-sec-0060"><h3 class="pmc_sec_title">Tumor microenvironment</h3>
<p>In contrast to liquid malignancies, the solid TME represents a heterogeneous and multifaceted intratumoral structure that contains neoplastic and nonneoplastic cells.<a href="#cncr70069-bib-0051" class="usa-link" aria-describedby="cncr70069-bib-0051">
<sup>51</sup>
</a>, <a href="#cncr70069-bib-0052" class="usa-link" aria-describedby="cncr70069-bib-0052">
<sup>52</sup>
</a>, <a href="#cncr70069-bib-0053" class="usa-link" aria-describedby="cncr70069-bib-0053">
<sup>53</sup>
</a> As a result, CRS in solid tumors may have varied pathophysiology compared to hematological malignancies (Figure <a href="#cncr70069-fig-0001" class="usa-link">1</a>). As CAR T‐cells typically circulate in the blood after infusion, liquid malignancies can be easily reached but there is difficulty accessing solid tumor cells due to high intratumoral pressure and the dense, abnormal TME. The TME offers immunologic challenges due to immunosuppressive cytokines and suppressor cells, the nature of which may vary by disease site and its histology.<a href="#cncr70069-bib-0054" class="usa-link" aria-describedby="cncr70069-bib-0054">
<sup>54</sup>
</a>, <a href="#cncr70069-bib-0055" class="usa-link" aria-describedby="cncr70069-bib-0055">
<sup>55</sup>
</a> Myeloid‐derived suppressor cells and regulatory T cells (Tregs) actively suppress the immune response as do cytokines like IL‐10 and TGF‐β that may in turn potentiate CRS severity.</p>
<figure class="fig xbox font-sm" id="cncr70069-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbaa/12374489/a95a87da50f2/CNCR-131-e70069-g001.jpg" loading="lazy" id="jats-graphic-1" height="559" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70069-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pathophysiology of cytokine release syndrome in solid organ malignancies.</p></figcaption></figure><p>Tumor endothelial cells differ from their normal counterparts due to the distinct conditions of the TME. Unlike the organized, hierarchical structure of normal vasculature, tumor vessels exhibit irregular and variable density. The endothelial cells often display abnormal morphology, with poor intercellular connections and extended cytoplasmic projections.<a href="#cncr70069-bib-0056" class="usa-link" aria-describedby="cncr70069-bib-0056">
<sup>56</sup>
</a> Structural abnormalities in TME vasculature promote fluid and plasma protein extravasation, raising interstitial fluid pressure. Further investigation is required to explore whether this facilitates cytokine transfer between the TME and systemic circulation, potentially amplifying a proinflammatory loop in CRS.</p></section><section id="cncr70069-sec-0070"><h3 class="pmc_sec_title">Tumor antigen</h3>
<p>Pre‐clinical data supports the theory that tumor antigen density impacts the degree of cytokine release. Majzner and colleagues<a href="#cncr70069-bib-0057" class="usa-link" aria-describedby="cncr70069-bib-0057">
<sup>57</sup>
</a> showed that the formation of CAR‐T synapses increases with surface antigen density, and even small changes in signaling motifs can alter the antigen density threshold required for T‐cell activation and cytokine secretion dramatically. Tumor burden and tumor expression (antigen copies per cell) are described as being strongly linked to the release of inflammatory cytokines such as IL‐6, and simulations have shown that the predicted IL‐6 levels vary depending on these factors.<a href="#cncr70069-bib-0058" class="usa-link" aria-describedby="cncr70069-bib-0058">
<sup>58</sup>
</a> These data suggest that the characteristics of the tumor—such as antigen density and distribution—are just as important as the engineering of the cell product itself.</p>
<p>Clinical data, however, reveal a more complex reality. High‐density, broadly expressed epithelial antigens can elicit robust CRS even in the context of modest tumor burden when the antigen is not confined to metastatic disease but is abundant across multiple organs.<a href="#cncr70069-bib-0004" class="usa-link" aria-describedby="cncr70069-bib-0004">
<sup>4</sup>
</a>, <a href="#cncr70069-bib-0059" class="usa-link" aria-describedby="cncr70069-bib-0059">
<sup>59</sup>
</a>, <a href="#cncr70069-bib-0060" class="usa-link" aria-describedby="cncr70069-bib-0060">
<sup>60</sup>
</a> Conversely, antigens that are both highly expressed and topographically restricted may mitigate the severity of CRS. For example, Claudin‐18.2 is highly expressed in gastric epithelium but largely absent from other essential tissues, thereby limiting off‐target macrophage activation. In the first‐in‐human trial of CLDN18.2‐CAR‐T cells for gastric and pancreatic cancer, 94% of patients experienced only grade 1–2 CRS, with no grade ≥3 events reported.<a href="#cncr70069-bib-0061" class="usa-link" aria-describedby="cncr70069-bib-0061">
<sup>61</sup>
</a> This mirrors early hemato‐oncology findings, where patients with low tumor burden exhibited lower cytokine peaks after CD19 CAR‐T therapy than those with bulky disease, highlighting total antigen load as a key driver of toxicity.<a href="#cncr70069-bib-0062" class="usa-link" aria-describedby="cncr70069-bib-0062">
<sup>62</sup>
</a> The combination of high antigen load, vital‐organ expression, and a cytokine‐rich TME makes antigen selection a critical lever for modulating CRS in solid tumors. Understanding and quantifying these factors will be essential for replicating the success of cellular immunotherapy in hematologic cancers without reproducing their toxicities.</p></section></section><section id="cncr70069-sec-0080"><h2 class="pmc_sec_title">CLINICAL TRIALS AND THE INCIDENCE OF CRS</h2>
<p>Recent clinical trial data (Table <a href="#cncr70069-tbl-0001" class="usa-link">1</a>) shows CRS to be common in BiTEs and CAR T‐cell therapy with incidences ranging from 51% to 90%. The complication is rare in ICIs at approximately 1%. Data is limited on the true incidence of CRS across all solid organ malignancies.</p></section><section id="cncr70069-sec-0090"><h2 class="pmc_sec_title">CLINICAL PRESENTATION AND GRADING</h2>
<p>Early detection and grading of CRS are crucial for patient safety, timely and appropriate therapeutic interventions, and management. This approach facilitates escalation to critical care when needed and allows for careful monitoring of syndrome progression.</p>
<section id="cncr70069-sec-0100"><h3 class="pmc_sec_title">Clinical manifestations</h3>
<p>The clinical presentation of CRS can vary from flu‐like symptoms to life‐threatening multiorgan dysfunction (Figure <a href="#cncr70069-fig-0002" class="usa-link">2</a>).<sup>7–10,47,63</sup> A limitation exists in that the majority of the clinical data and experience is from liquid malignancies. Fever is a hallmark and typically the first clinical sign. Fatigue, myalgia, headache, and chills are often reported in early stages of the illness along with gastrointestinal symptoms such as diarrhea and vomiting. Severe CRS can progress to hypotension and hypoxia such that intensive care and organ supports are required in the form of vasopressors, mechanical ventilation, and renal replacement therapy. Disseminated intravascular coagulation, capillary leak syndrome, liver dysfunction, and acute kidney injury are also recognized complications of the inflammatory process. Neurotoxicity has been described to occur either concurrently or after other features of CRS and may manifest as encephalopathy, delirium, seizures, and other neurological changes. This is now defined as a separate entity of immune effector cell‐associated neurotoxicity syndrome (ICANS) because of its distinct timing, response to intervention, and unclear pathophysiology.<a href="#cncr70069-bib-0008" class="usa-link" aria-describedby="cncr70069-bib-0008">
<sup>8</sup>
</a>, <a href="#cncr70069-bib-0063" class="usa-link" aria-describedby="cncr70069-bib-0063">
<sup>63</sup>
</a>
</p>
<figure class="fig xbox font-sm" id="cncr70069-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbaa/12374489/ad2c45d029ce/CNCR-131-e70069-g002.jpg" loading="lazy" id="jats-graphic-3" height="922" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/cncr70069-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Clinical presentation of cytokine release syndrome in solid organ malignancies.</p></figcaption></figure><p>The time‐to‐onset and duration of CRS is variable and can differ depending on the type of immunotherapy. Based on current data, which is hematologic malignancy predominant, CRS can occur within minutes to hours after antibody therapy,<a href="#cncr70069-bib-0009" class="usa-link" aria-describedby="cncr70069-bib-0009">
<sup>9</sup>
</a> within days to weeks of adoptive T‐cell therapies coinciding with peak T‐cell expansion,<a href="#cncr70069-bib-0048" class="usa-link" aria-describedby="cncr70069-bib-0048">
<sup>48</sup>
</a> and usually within a week to 30 days of ICI therapy.<a href="#cncr70069-bib-0064" class="usa-link" aria-describedby="cncr70069-bib-0064">
<sup>64</sup>
</a> Mild CRS tends to resolve within a few days, whereas the severe form may persist for several weeks or longer.<a href="#cncr70069-bib-0065" class="usa-link" aria-describedby="cncr70069-bib-0065">
<sup>65</sup>
</a>
</p>
<p>In addition to sepsis, other differentials should be considered and excluded. These include decompensation of heart failure, thromboembolism, allergic reaction, and tumor progression. Although tumor lysis syndrome is a common oncological emergency in hematological malignancies, it is extremely rare in solid organ tumors but carries a high mortality risk.<a href="#cncr70069-bib-0066" class="usa-link" aria-describedby="cncr70069-bib-0066">
<sup>66</sup>
</a>, <a href="#cncr70069-bib-0067" class="usa-link" aria-describedby="cncr70069-bib-0067">
<sup>67</sup>
</a>
</p></section><section id="cncr70069-sec-0110"><h3 class="pmc_sec_title">Laboratory testing</h3>
<p>CRS is marked by notable changes in numerous laboratory parameters. Although cytokine abnormalities are well‐documented, real‐time cytokine data are rarely accessible in most hospitals or clinical areas, as mentioned in several articles, limiting their utility for timely grading and management.<a href="#cncr70069-bib-0008" class="usa-link" aria-describedby="cncr70069-bib-0008">
<sup>8</sup>
</a>, <a href="#cncr70069-bib-0009" class="usa-link" aria-describedby="cncr70069-bib-0009">
<sup>9</sup>
</a>, <a href="#cncr70069-bib-0031" class="usa-link" aria-describedby="cncr70069-bib-0031">
<sup>31</sup>
</a>, <a href="#cncr70069-bib-0065" class="usa-link" aria-describedby="cncr70069-bib-0065">
<sup>65</sup>
</a> Although IL‐6 is involved in the pathophysiology of CRS, its levels do not necessarily correlate with disease severity or response to treatment.<a href="#cncr70069-bib-0068" class="usa-link" aria-describedby="cncr70069-bib-0068">
<sup>68</sup>
</a> This is based on translational research through prospective clinical trials to identify predictive biomarkers of CRS in CAR T‐cell therapy for hematological malignancies.<a href="#cncr70069-bib-0068" class="usa-link" aria-describedby="cncr70069-bib-0068">
<sup>68</sup>
</a> C‐reactive protein (CRP) is both widely accessible and cost‐effective, initially showing promise as a useful surrogate biomarker for CRS.<a href="#cncr70069-bib-0068" class="usa-link" aria-describedby="cncr70069-bib-0068">
<sup>68</sup>
</a>, <a href="#cncr70069-bib-0069" class="usa-link" aria-describedby="cncr70069-bib-0069">
<sup>69</sup>
</a> CRP lacks specificity for this syndrome, however, and its variability, along with the delay in its elevation relative to clinical worsening, limits its practical utility in clinical settings. Clinicians must also bear in mind that CRS and sepsis can occur concomitantly, necessitating a low threshold for suspicion of each.</p>
<p>Serum cytokine levels, such INF‐γ, are frequently higher in patients with CRS due to CAR T‐cell therapy than in patients with CRS induced by sepsis, who often have higher levels of circulating IL‐1β, procalcitonin, and other markers of damage to endothelia. Combinations of assays to rule out infection and measure serum cytokines can therefore assist in identifying the trigger for massive cytokine release.<a href="#cncr70069-bib-0070" class="usa-link" aria-describedby="cncr70069-bib-0070">
<sup>70</sup>
</a>, <a href="#cncr70069-bib-0071" class="usa-link" aria-describedby="cncr70069-bib-0071">
<sup>71</sup>
</a> Although some specialized centers may have access to these assays, they are not yet widely used in clinical practice.</p></section><section id="cncr70069-sec-0120"><h3 class="pmc_sec_title">Grading</h3>
<p>Several other grading systems for CRS had been produced before the current American Society for Transplantation and Cellular Therapy (ASTCT) grading system (Table <a href="#cncr70069-tbl-0002" class="usa-link">2</a>), which was published in 2019. This system grades CRS from 1–5, based on clinical features, and was developed in response to considerable variation in the assessment and grading of toxicities across clinical trials and institutions. This made it challenging to compare product safety and impeded the development of effective management strategies.<a href="#cncr70069-bib-0008" class="usa-link" aria-describedby="cncr70069-bib-0008">
<sup>8</sup>
</a> The earlier systems included CTCAE versions 4.0‐5.0,<a href="#cncr70069-bib-0072" class="usa-link" aria-describedby="cncr70069-bib-0072">
<sup>72</sup>
</a>, <a href="#cncr70069-bib-0073" class="usa-link" aria-describedby="cncr70069-bib-0073">
<sup>73</sup>
</a> and the Lee,<a href="#cncr70069-bib-0009" class="usa-link" aria-describedby="cncr70069-bib-0009">
<sup>9</sup>
</a> Penn,<a href="#cncr70069-bib-0074" class="usa-link" aria-describedby="cncr70069-bib-0074">
<sup>74</sup>
</a> MSKCC,<a href="#cncr70069-bib-0075" class="usa-link" aria-describedby="cncr70069-bib-0075">
<sup>75</sup>
</a> and CARTOX<a href="#cncr70069-bib-0063" class="usa-link" aria-describedby="cncr70069-bib-0063">
<sup>63</sup>
</a> criteria.</p>
<section class="tw xbox font-sm" id="cncr70069-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>ASTCT CRS consensus grading.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<thead><tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">CRS parameter</th>
<th align="left" rowspan="1" colspan="1">Grade 1</th>
<th align="left" rowspan="1" colspan="1">Grade 2</th>
<th align="left" rowspan="1" colspan="1">Grade 3</th>
<th align="left" rowspan="1" colspan="1">Grade 4</th>
<th align="left" rowspan="1" colspan="1">Grade 5</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fever</td>
<td align="left" valign="top" rowspan="1" colspan="1">Temperature ≥38°C</td>
<td align="left" valign="top" rowspan="1" colspan="1">Temperature ≥38°C</td>
<td align="left" valign="top" rowspan="1" colspan="1">Temperature ≥38°C</td>
<td align="left" valign="top" rowspan="1" colspan="1">Temperature ≥38°C</td>
<td rowspan="5" align="left" valign="top" colspan="1">Death due to CRS</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">with</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Hypotension</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
<td align="left" valign="top" rowspan="1" colspan="1">Not requiring vasopressors</td>
<td align="left" valign="top" rowspan="1" colspan="1">Requiring a vasopressor with or without vasopressin</td>
<td align="left" valign="top" rowspan="1" colspan="1">Requiring multiple vasopressors (excluding vasopressin)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">And/or</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Hypoxia</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
<td align="left" valign="top" rowspan="1" colspan="1">Requiring low‐flow nasal cannula or blow‐by</td>
<td align="left" valign="top" rowspan="1" colspan="1">Requiring high‐flow nasal cannula, facemask, nonrebreather mask, or Venturi mask</td>
<td align="left" valign="top" rowspan="1" colspan="1">Requiring positive pressure (e.g., CPAP, BiPAP, intubation, and mechanical ventilation)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cncr70069-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="cncr70069-note-0002"><p>
<em>Note</em>: Organ toxicities associated with CRS may be graded according to CTCAE v5.0 but they do not influence CRS grading.<a href="#cncr70069-bib-0008" class="usa-link" aria-describedby="cncr70069-bib-0008">
<sup>8</sup>
</a>
</p></div>
<div class="fn" id="cncr70069-note-0003"><p>Abbreviations: ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events.</p></div>
</div></section><p>The ASTCT system has been developed based on liquid malignancy data but is currently being used by many clinicians for solid organ malignancies.<a href="#cncr70069-bib-0004" class="usa-link" aria-describedby="cncr70069-bib-0004">
<sup>4</sup>
</a>, <a href="#cncr70069-bib-0076" class="usa-link" aria-describedby="cncr70069-bib-0076">
<sup>76</sup>
</a> It uses observable clinical parameters, such as fever, hypotension, and hypoxia, to grade CRS, enabling easy implementation across health care settings. Although it recognizes laboratory markers like cytokine levels and CRP, these are excluded from grading due to limited real‐time standardization and availability. To ensure consistent grading, the system provides clear definitions for key symptoms and specifies criteria for CRS resolution, accounting for anti‐cytokine therapies, and requiring all CRS‐related signs and symptoms to fully subside.</p></section><section id="cncr70069-sec-0130"><h3 class="pmc_sec_title">Defining resolution of CRS</h3>
<p>As per the ASTCT system, patients remain classified as having CRS until all symptoms prompting the diagnosis have resolved, not just fever. Following tocilizumab administration, fever typically subsides within hours, although other CRS symptoms may persist for longer. Fever is required for CRS grading, and cytokine therapies are used only in patients meeting CRS criteria, but the grade can be lowered as hemodynamic stability and oxygen levels improve post‐treatment. Severe CRS is generally considered resolved when fever subsides and the patient no longer requires supplemental oxygen or vasopressor support.</p></section></section><section id="cncr70069-sec-0140"><h2 class="pmc_sec_title">MANAGEMENT</h2>
<p>The overarching goal in managing CRS for cancer patients undergoing immunotherapy is to prevent life‐threatening complications while preserving the potential for a favorable antitumor response. Many immune cell therapies for solid tumors, to date, are given in a palliative rather than curative setting. This is likely to change substantially in the coming years. Appropriate and individualized ceilings of care should therefore be established, with patient involvement, at the beginning of immune therapy and reviewed upon recognition of toxicity such as CRS. If infection cannot be ruled out, initiating empiric antibiotic therapy is advised, especially in those with neutropenia. Although current treatment algorithms are largely extrapolated from hematological malignancies, data from more than 200 recipients of immune‐effector cell therapies for solid tumors show that approximately 90% of grade ≥2 CRS episodes resolved following ASTCT‐guided administration of tocilizumab, with or without adjunctive corticosteroids—an efficacy profile that closely parallels outcomes in B‐cell CAR‐T cohorts.<a href="#cncr70069-bib-0076" class="usa-link" aria-describedby="cncr70069-bib-0076">
<sup>76</sup>
</a>, <a href="#cncr70069-bib-0077" class="usa-link" aria-describedby="cncr70069-bib-0077">
<sup>77</sup>
</a> Clinicians must bear in mind that guidelines for CRS in solid organ malignancies specifically are not currently available.</p>
<section id="cncr70069-sec-0150"><h3 class="pmc_sec_title">Supportive care</h3>
<p>Grade 1 CRS is managed with supportive care, including close monitoring of organ function and targeted interventions as needed such as resuscitation with intravenous (iv) crystalloid and anti‐pyretics. Early proactive involvement of intensive care and multidisciplinary teams is recommended. Although fluid resuscitation can improve blood pressure, it may worsen edema in the context of impaired cardiac or renal function, so vasopressor support is often required to prevent fluid overload. Grade 2 and higher require further intervention as described below.</p>
<p>Patients with higher grades of CRS (grades 3–4) have been shown to have close to 10 times the likelihood of developing acute kidney injury (AKI) compared to those with milder grades of CRS following CAR T‐cell therapy.<a href="#cncr70069-bib-0078" class="usa-link" aria-describedby="cncr70069-bib-0078">
<sup>78</sup>
</a> In that study, most kidney injuries appeared to be due to decreased kidney perfusion and improved with hemodynamic support. Furthermore, the severity of AKI has been found to correlate with the grade of CRS.<a href="#cncr70069-bib-0079" class="usa-link" aria-describedby="cncr70069-bib-0079">
<sup>79</sup>
</a> Electrolyte disorders are also an established adverse effect of immune cell therapies, especially in CRS, with hypokalemia, hyponatremia, and hypophosphatemia being most common.<a href="#cncr70069-bib-0063" class="usa-link" aria-describedby="cncr70069-bib-0063">
<sup>63</sup>
</a>, <a href="#cncr70069-bib-0078" class="usa-link" aria-describedby="cncr70069-bib-0078">
<sup>78</sup>
</a>, <a href="#cncr70069-bib-0080" class="usa-link" aria-describedby="cncr70069-bib-0080">
<sup>80</sup>
</a> Regular monitoring and replacement are advised in a high dependency setting. Serial blood tests should be conducted to monitor for cytopenias or signs of DIC. American Society of Clinical Oncology (ASCO) guidelines, built almost entirely on evidence from hematological malignancies, recommend regular measurement of CRP, ferritin, and cytokines, where available, to help interpret the patient's clinical course and inform future clinical trials.<a href="#cncr70069-bib-0081" class="usa-link" aria-describedby="cncr70069-bib-0081">
<sup>81</sup>
</a> IL‐6, TNF‐α, and IFN‐γ are the more commonly measured cytokines. Even in centers with in‐house testing, however, results can take more than 24 hours.</p></section><section id="cncr70069-sec-0160"><h3 class="pmc_sec_title">IL‐6 receptor antagonists</h3>
<p>Tocilizumab is a humanized immunoglobulin G1k monoclonal antibody targeting the human IL‐6 receptor (IL‐6R), which works by preventing IL‐6 from binding to both cell‐associated and soluble IL‐6Rs. This action inhibits both classical and trans‐signaling of IL‐6 with the goal of dampening massive cytokine release. Tocilizumab was approved by the FDA in 2017 for severe or life‐threatening CRS induced by CAR T‐cell therapy in adults and pediatric patients aged 2 years and older.<a href="#cncr70069-bib-0082" class="usa-link" aria-describedby="cncr70069-bib-0082">
<sup>82</sup>
</a> Tocilizumab is the first‐line treatment for CRS.<sup>7,83</sup> Current guidelines suggest its use in patients with ASTCT grade 2 CRS and, in certain cases, for those with ASTCT grade 1 CRS.<a href="#cncr70069-bib-0083" class="usa-link" aria-describedby="cncr70069-bib-0083">
<sup>83</sup>
</a> Reassuringly, data have shown that tocilizumab does not impact CAR T‐cell expansion and therefore the risk of reducing efficacy is low.<a href="#cncr70069-bib-0084" class="usa-link" aria-describedby="cncr70069-bib-0084">
<sup>84</sup>
</a>
</p>
<p>For grade 2 CRS and above, or grade 1 CRS persisting for more than 3 days, tocilizumab may be initiated at 8 mg/kg (up to a maximum dose of 800 mg) and can be administered every 8 hours, with a maximum of three doses within a 24‐hour period. It may also be considered for specific organ toxicities, including severe acute kidney or liver injury, heart failure with reduced ejection fraction, or significant electrolyte imbalances.<a href="#cncr70069-bib-0085" class="usa-link" aria-describedby="cncr70069-bib-0085">
<sup>85</sup>
</a> However, most patients experiencing severe organ toxicities typically already present with grade 2 or higher CRS. If effective, symptoms typically improve within hours to 2 days of administration. This reflects the rapid bioavailability of tocilizumab for which the maximal serum concentration can be reached within 2 hours.<a href="#cncr70069-bib-0086" class="usa-link" aria-describedby="cncr70069-bib-0086">
<sup>86</sup>
</a> Tocilizumab is generally well tolerated with few adverse effects reported in studies evaluating its use in rheumatological conditions. These were predominantly infection, neutropenia, gastrointestinal complaints, rash, and headache.<a href="#cncr70069-bib-0087" class="usa-link" aria-describedby="cncr70069-bib-0087">
<sup>87</sup>
</a>, <a href="#cncr70069-bib-0088" class="usa-link" aria-describedby="cncr70069-bib-0088">
<sup>88</sup>
</a> It does, however, carry a risk of severe bacterial infections.<a href="#cncr70069-bib-0089" class="usa-link" aria-describedby="cncr70069-bib-0089">
<sup>89</sup>
</a> Targeting IL‐6R with tocilizumab has not proven effective for preventing or treating neurotoxicity in ICANS, which may be due to its limited distribution into the central nervous system.<a href="#cncr70069-bib-0090" class="usa-link" aria-describedby="cncr70069-bib-0090">
<sup>90</sup>
</a>, <a href="#cncr70069-bib-0091" class="usa-link" aria-describedby="cncr70069-bib-0091">
<sup>91</sup>
</a>
</p>
<p>Recent work by Daoudlarian et al.<a href="#cncr70069-bib-0092" class="usa-link" aria-describedby="cncr70069-bib-0092">
<sup>92</sup>
</a> has expanded the therapeutic rationale for IL‐6 blockade for ICI–driven hyper‐inflammation. In ICI therapy, corticosteroids are often administered initially for suspected immune‐related adverse events and tocilizumab can be added for irHLH.<a href="#cncr70069-bib-0093" class="usa-link" aria-describedby="cncr70069-bib-0093">
<sup>93</sup>
</a>, <a href="#cncr70069-bib-0094" class="usa-link" aria-describedby="cncr70069-bib-0094">
<sup>94</sup>
</a> This contrasts with CRS guidelines that advise tocilizumab first and corticosteroids as second‐line.<a href="#cncr70069-bib-0008" class="usa-link" aria-describedby="cncr70069-bib-0008">
<sup>8</sup>
</a>, <a href="#cncr70069-bib-0065" class="usa-link" aria-describedby="cncr70069-bib-0065">
<sup>65</sup>
</a>, <a href="#cncr70069-bib-0082" class="usa-link" aria-describedby="cncr70069-bib-0082">
<sup>82</sup>
</a> In a biomarker‐directed study of 35 adults who developed hyperinflammatory conditions such as immune‐related hemophagocytic lymphohistiocytosis (irHLH), immune‐related CRS (irCRS), or sepsis during ICI therapy, the investigators used biomarker profiling to identify means of differentiating between these conditions. An additional aim of this study was to retrospectively assess how effectively tocilizumab controlled high‐grade steroid‐refractory irCRS. Ferritin and hepatocyte‐growth factor (HGF) each provided 100% positive and negative predictive value for distinguishing irCRS from irHLH, whereas serum CXCL9 levels identified patients likely to require escalation beyond corticosteroids. Twelve individuals with grade‐3 irCRS refractory to ≥48 hours of high‐dose methylprednisolone received tocilizumab 8 mg/kg. All achieved complete clinical and biochemical remission within 24 hours. No patients relapsed over a median 9‐week follow‐up. Tumor control was preserved, with seven maintaining partial responses and the remainder stable disease at first re‐staging. Beyond corroborating the therapeutic value of IL‐6 blockade, the study underscores how biomarkers such as ferritin, HGF, and CXCL9 can be useful in guiding treatment escalation.</p></section><section id="cncr70069-sec-0170"><h3 class="pmc_sec_title">Tocilizumab‐refractory CRS</h3>
<p>Corticosteroids are an agreed second‐line therapy for CAR T‐cell–related CRS that is refractory to tocilizumab therapy. Although indications vary slightly among recent guidelines,<a href="#cncr70069-bib-0065" class="usa-link" aria-describedby="cncr70069-bib-0065">
<sup>65</sup>
</a>, <a href="#cncr70069-bib-0081" class="usa-link" aria-describedby="cncr70069-bib-0081">
<sup>81</sup>
</a>, <a href="#cncr70069-bib-0095" class="usa-link" aria-describedby="cncr70069-bib-0095">
<sup>95</sup>
</a>, <a href="#cncr70069-bib-0096" class="usa-link" aria-describedby="cncr70069-bib-0096">
<sup>96</sup>
</a> ASCO guidelines advise administration of glucocorticoids in patients with grade 3 CRS or higher, or those with grade 2 CRS who have not responded clinically to two iv fluid boluses (dosed at physician’s discretion) and one and two doses of tocilizumab. Dosing depends on grading. For grade 2 CRS, dexamethasone 10 mg iv every 12 hours is advised. For grade 3, dexamethasone 10 mg iv every 6 h with taper on improvement. For grade 4 CRS, it is advised to escalate to methylprednisolone 500 mg iv every 12 h with taper as clinically appropriate. If symptoms remain refractory following glucocorticoid therapy for any grade of CRS, treatment should proceed based on guidelines for the next highest CRS grade. For refractory severe CRS, it is recommended to administer methylprednisolone at 1000 mg iv every 12 hours.<a href="#cncr70069-bib-0081" class="usa-link" aria-describedby="cncr70069-bib-0081">
<sup>81</sup>
</a> Corticosteroids pose a significant risk of further immunosuppression, carrying an amplified threat of opportunistic bacterial, viral, and fungal infections.<a href="#cncr70069-bib-0097" class="usa-link" aria-describedby="cncr70069-bib-0097">
<sup>97</sup>
</a> Other side effects include worsening of edema, insulin resistance leading to hyperglycemia, and neuropsychiatric syndromes. One must also consider the long‐term effects of repeated corticosteroid exposure in cancer patients throughout their disease journey.</p>
<p>Conflicting data exists as to the effect of glucocorticoids on CAR T‐cell efficacy and overall survival. In early studies, patients who were treated for CRS with glucocorticoids demonstrated a decrease in blood CAR T‐cell levels, reduced CAR T‐cell persistence, and more frequent relapses of malignancy.<a href="#cncr70069-bib-0069" class="usa-link" aria-describedby="cncr70069-bib-0069">
<sup>69</sup>
</a>, <a href="#cncr70069-bib-0098" class="usa-link" aria-describedby="cncr70069-bib-0098">
<sup>98</sup>
</a>, <a href="#cncr70069-bib-0099" class="usa-link" aria-describedby="cncr70069-bib-0099">
<sup>99</sup>
</a> Although these findings have not been supported by recent data,<a href="#cncr70069-bib-0100" class="usa-link" aria-describedby="cncr70069-bib-0100">
<sup>100</sup>
</a>, <a href="#cncr70069-bib-0101" class="usa-link" aria-describedby="cncr70069-bib-0101">
<sup>101</sup>
</a> there is no available analysis for the long‐term effects of glucocorticoids on patients with solid organ tumors who develop CRS. As discussed, BiTEs are often used in solid organ tumors in conjunction with CAR T‐cell therapy which allows targeting to tumors with high specificity. The effects of glucocorticoids on BiTEs are not definitive but in vitro studies suggest a potential amelioration of T‐cell exhaustion (i.e., improving persistence).<a href="#cncr70069-bib-0102" class="usa-link" aria-describedby="cncr70069-bib-0102">
<sup>102</sup>
</a>
</p></section><section id="cncr70069-sec-0180"><h3 class="pmc_sec_title">Other agents</h3>
<p>Other cytokine antagonists are also available for use in steroid‐refractory CRS or patients in which steroid‐sparing is necessary. Clinical and real‐world data for these therapies, however, is more limited. The ASCO guidelines suggest the use of siltuximab, anakinra, or ruloxitinib as the next line in management for those with CRS from CAR T‐cell related toxicity. As stated before, this draws principally on data generated in hematologic cancers and clinician discretion is advised.</p>
<p>Siltuximab is an IL‐6 receptor antagonist<a href="#cncr70069-bib-0063" class="usa-link" aria-describedby="cncr70069-bib-0063">
<sup>63</sup>
</a>, <a href="#cncr70069-bib-0103" class="usa-link" aria-describedby="cncr70069-bib-0103">
<sup>103</sup>
</a> that blocks immune effector cell activation via both classical and trans‐signaling pathways. It has a higher affinity for IL‐6 than tocilizumab has for IL‐6R but its clinical data are more limited. There is emerging retrospective trial data to support its efficacy in patients who had CAR T‐cell associated CRS including those who have failed first‐line therapy with tocilizumab. Solid organ tumors were not included in these data.<a href="#cncr70069-bib-0104" class="usa-link" aria-describedby="cncr70069-bib-0104">
<sup>104</sup>
</a>
</p>
<p>Anakinra is an IL‐1 receptor antagonist that has shown some success in treating refractory CRS in hematological malignancies.<a href="#cncr70069-bib-0105" class="usa-link" aria-describedby="cncr70069-bib-0105">
<sup>105</sup>
</a> There are no current data describing its use in solid organ malignancies.</p>
<p>Ruxolitinib, an oral JAK1/2 inhibitor, has been shown to rapidly reduce CRS‐related cytokines, including IL‐6, IL‐10, sCD25, TNF‐γ, and serum ferritin, following administration in a small number of patients with steroid refractory CRS.<a href="#cncr70069-bib-0106" class="usa-link" aria-describedby="cncr70069-bib-0106">
<sup>106</sup>
</a> Large clinical trial and safety data is lacking with no available evidence in solid organ tumors.</p>
<p>Given the limited evidence for these agents in solid organ tumors, it is essential to reassess the patient’s response, ceiling of care, and suitability before initiating therapy, as the treatment may ultimately prove ineffective.</p></section><section id="cncr70069-sec-0190"><h3 class="pmc_sec_title">Immunotherapy rechallenge</h3>
<p>Repeated or continuous dosing immunotherapies for solid tumors—most prominently ICIs and BiTEs—create a unique therapeutic dilemma when CRS occurs. Because these agents are often prescribed with palliative rather than curative intent, the clinician must decide whether the potential gain in tumor control justifies the risk of recurrent toxicity after the episode has settled. Data for rechallenging in CRS are limited but there is evidence to suggest that rechallenging with ICIs after other irAEs may not improve overall survival for patients.<a href="#cncr70069-bib-0104" class="usa-link" aria-describedby="cncr70069-bib-0104">
<sup>104</sup>
</a> Evidence to guide these judgments, although thin, is reassuring at lower CRS grades. In the Karolinska observational cohort of 2672 ICI‐treated patients, 19 individuals were rechallenged after grade 1–2 CRS and three experienced another episode, each again grade ≤2.<sup>65</sup> A smaller series of ICI‐related CRS likewise documents low recurrence when therapy is resumed after grade 1–2 events.<a href="#cncr70069-bib-0105" class="usa-link" aria-describedby="cncr70069-bib-0105">
<sup>105</sup>
</a> Data on BiTEs such as tarlatamab are currently limited to case reports.<a href="#cncr70069-bib-0106" class="usa-link" aria-describedby="cncr70069-bib-0106">
<sup>106</sup>
</a> Although early outcomes appear promising, clinicians should exercise caution due to the absence of robust clinical trial data to date. This may suggest rechallenging after mild CRS in solid organ tumors is relatively safe and should be taken on a case‐by‐case basis with MDT and patient involvement.</p>
<p>When CRS has resolved, three variables can help determine whether retreatment is reasonable. First, the therapeutic goal: tarlatamab in extensive‐stage small cell lung cancer and tebentafusp in first‐line uveal melanoma carry disease‐controlling (if not curative) ambitions, whereas late‐line ICIs are often palliative. Second, on‐treatment efficacy: objective tumor regression or clear symptomatic benefit strengthens the argument for resumption. Third, patient factors—performance status, comorbidities, and personal risk tolerance—must weigh heavily, given that re‐exposure invariably carries risk.</p></section><section id="cncr70069-sec-0200"><h3 class="pmc_sec_title">Prevention</h3>
<p>To prevent CRS developing into severe grades, administering a lower dose of immune cell therapy to patients with a high tumor burden has proven effective in hematologic malignancies and may also be relevant for solid tumors.<a href="#cncr70069-bib-0069" class="usa-link" aria-describedby="cncr70069-bib-0069">
<sup>69</sup>
</a>, <a href="#cncr70069-bib-0107" class="usa-link" aria-describedby="cncr70069-bib-0107">
<sup>107</sup>
</a> One study employed risk‐adapted CAR T‐cell dosing based on bone marrow blast percentage, resulting in a reduced incidence of severe CRS and neurotoxicity in patients with substantial tumor burdens. This strategy is based on the correlation between CRS severity and tumor burden, where a higher tumor load offers more antigen targets for CAR T‐cells, leading to heightened T‐cell activation, proliferation, and cytokine release.<a href="#cncr70069-bib-0108" class="usa-link" aria-describedby="cncr70069-bib-0108">
<sup>108</sup>
</a> Preclinical trials indicate that step‐up dosing or subcutaneous administration of bispecific antibodies may reduce the risk of developing CRS, but these approaches do not yet to have enough evidence to become standard practice.<a href="#cncr70069-bib-0109" class="usa-link" aria-describedby="cncr70069-bib-0109">
<sup>109</sup>
</a>, <a href="#cncr70069-bib-0110" class="usa-link" aria-describedby="cncr70069-bib-0110">
<sup>110</sup>
</a>
</p>
<p>Ultimately, T‐cell therapies for solid tumors remain largely in clinical trial, with each defining its own CRS prophylaxis and management strategies. Although adherence to trial‐specific protocols is essential at present, the development of unified, evidence‐based management guidelines will be crucial as these therapies move toward broader clinical application.</p></section></section><section id="cncr70069-sec-0210"><h2 class="pmc_sec_title">FUTURE TREATMENTS</h2>
<section id="cncr70069-sec-0220"><h3 class="pmc_sec_title">Targeting alternative inflammatory pathway components</h3>
<p>Itacitinib is a potent, selective JAK1 inhibitor with broad anti‐inflammatory activity for which there is phase 2 randomized control trial data to support its potential future use as a preventative therapy for those receiving immune cell therapy.<a href="#cncr70069-bib-0111" class="usa-link" aria-describedby="cncr70069-bib-0111">
<sup>111</sup>
</a> Phase 3 trial data are not yet available, nor are there data to support treatment in solid organ tumors to date. Prophylaxis for patients with hematological malignancies receiving axicabtagene ciloleucel (CAR T‐cell agent) resulted in a lower incidence of CRS and was generally well tolerated.</p>
<p>TNF‐α, produced by activated T‐cells, is a potential primary mediator in triggering a cascade of inflammatory cytokine release from monocytes, leading to the systemic CRS response. Etanercept, a TNF‐α inhibitor, has therefore been suggested as a treatment and has been used with mixed results in hematological malignancies.<a href="#cncr70069-bib-0011" class="usa-link" aria-describedby="cncr70069-bib-0011">
<sup>11</sup>
</a>, <a href="#cncr70069-bib-0112" class="usa-link" aria-describedby="cncr70069-bib-0112">
<sup>112</sup>
</a> Case report data support some success in solid organ malignancy with ICI‐associated CRS after failed use of tocilizumab and steroids but other cases may not respond in a similar way.<a href="#cncr70069-bib-0014" class="usa-link" aria-describedby="cncr70069-bib-0014">
<sup>14</sup>
</a> Further research is needed to determine its efficacy and safety, as well as its impact on antitumor responses.</p>
<p>Dasatinib is a tyrosine kinase inhibitor that has in vitro evidence for reducing CRS toxicity related to BiTE therapy and case reports in CAR T‐cell treatment.<a href="#cncr70069-bib-0113" class="usa-link" aria-describedby="cncr70069-bib-0113">
<sup>113</sup>
</a>, <a href="#cncr70069-bib-0114" class="usa-link" aria-describedby="cncr70069-bib-0114">
<sup>114</sup>
</a> Lenzilumab is a monoclonal antibody that neutralizes GM‐CSF, a glycoprotein that promotes macrophage differentiation that in turn leads to the production of IL‐6 and TNF‐α, among others.<a href="#cncr70069-bib-0114" class="usa-link" aria-describedby="cncr70069-bib-0114">
<sup>114</sup>
</a> This has also shown some in vitro success. Clinical trial data are not yet available for these potential future therapies.</p></section><section id="cncr70069-sec-0230"><h3 class="pmc_sec_title">Removal of inflammatory mediators</h3>
<p>Case reports have demonstrated success for therapeutic plasma exchange (TPE), also known as plasmapheresis, in cases of severe refractory CRS following CAR T‐cell therapy for which tocilizumab and glucocorticoids have failed.<a href="#cncr70069-bib-0115" class="usa-link" aria-describedby="cncr70069-bib-0115">
<sup>115</sup>
</a>, <a href="#cncr70069-bib-0116" class="usa-link" aria-describedby="cncr70069-bib-0116">
<sup>116</sup>
</a> There has also been success in TPE lowering serum levels of IL‐6, CRP, and other inflammatory markers in patients with severe SARS‐Cov‐2–related inflammatory syndrome.<a href="#cncr70069-bib-0117" class="usa-link" aria-describedby="cncr70069-bib-0117">
<sup>117</sup>
</a> The effect of TPE on overall survival is unclear as we do not have sufficient evidence to estimate its effect on the efficacy of immune cell therapy. TPE has been successful in a single case report for a patient with a solid organ tumor, hepatitis B virus‐related metastatic hepatocellular carcinoma with lung metastases, who developed severe refractory CRS after treatment with T‐cell receptor‐engineered T‐cell immunotherapy.<a href="#cncr70069-bib-0118" class="usa-link" aria-describedby="cncr70069-bib-0118">
<sup>118</sup>
</a> We do not yet have supportive evidence from clinical trials.</p></section><section id="cncr70069-sec-0240"><h3 class="pmc_sec_title">Suicide genes in immune cell therapy</h3>
<p>Suicide gene systems involve engineering T cells with a “suicide” gene that can be activated by administering an external agent to induce apoptosis in the modified T cells.<a href="#cncr70069-bib-0119" class="usa-link" aria-describedby="cncr70069-bib-0119">
<sup>119</sup>
</a> Genes like inducible caspase 9 (iCasp9) or herpes simplex virus thymidine kinase (HSV‐TK) can be triggered by specific drugs to potentially assist with controlling adverse effects. For example, the HSV‐TK gene is one of the most frequently studied suicide genes. It encodes the viral enzyme HSV‐TK, which, in the presence of the drug ganciclovir, converts the drug into its active triphosphate form in pre‐clinical data. This leads to DNA chain termination and cell death in the T cells expressing the suicide gene.<a href="#cncr70069-bib-0120" class="usa-link" aria-describedby="cncr70069-bib-0120">
<sup>120</sup>
</a> Although limited to humanized mouse models thus far, administering an agent like AP1903 alongside the iCasp9 construct has shown effectiveness in T and CAR T‐cells for alleviating CRS‐like symptoms and has demonstrated a decrease in proinflammatory cytokine levels.<a href="#cncr70069-bib-0121" class="usa-link" aria-describedby="cncr70069-bib-0121">
<sup>121</sup>
</a>
</p></section></section><section id="cncr70069-sec-0250"><h2 class="pmc_sec_title">CONCLUSION</h2>
<p>Although the management of CRS in hematological malignancies is well‐researched with established clinical guidelines, CRS in solid organ tumors presents a unique and evolving challenge. Balancing the reduction of inflammation with the preservation of the antitumor immune response is crucial, requiring a patient‐centered approach and personalized care strategies for individual treatment goals. Although supportive care is sufficient for mild CRS, higher‐grade cases often require targeted interventions such as tocilizumab, corticosteroids, or alternative agents for refractory symptoms. Timely involvement of a multidisciplinary team and early escalation to intensive care are often required and should be approached in a proactive manner. The decision to resume immunotherapy, particularly in the context of malignancies being treated with palliative intent, remains a nuanced decision that requires a personalized approach.</p>
<p>Ongoing research is crucial to developing innovative therapeutic strategies. Potential future treatments, such as targeting other components of the cytokine cascade, plasma exchange, and suicide gene systems, show promise in preventing and managing CRS. Continued advancements in this field hold the potential to provide safer and more effective immunotherapy options for patients with solid tumors, paving the way for improved outcomes and enhanced patient care.</p></section><section id="cncr70069-sec-0260"><h2 class="pmc_sec_title">AUTHOR CONTRIBUTIONS</h2>
<p>
<strong>David Synnott:</strong> Conceptualization, writing–original draft, and writing–review and editing. <strong>David O'Reilly:</strong> Conceptualization, writing–original draft, and writing–review and editing. <strong>Declan de Freitas:</strong> Conceptualization, supervision, and writing–review and editing. <strong>Jarushka Naidoo:</strong> Conceptualization, supervision, and writing–review and editing.</p></section><section id="cncr70069-sec-0270"><h2 class="pmc_sec_title">CONFLICT OF INTEREST STATEMENT</h2>
<p>David O’Reilly reports consulting fees from Janssen; and conference attendance for Takeda, MSD, and Servier. Jarushka Naidoo reports consulting fees from Bristol‐Myers Squibb, Roche/Genentech, Amgen, NGM Pharmaceuticals, Takeda, Pfizer, Elevation Oncology, AbbVie, Kaleido Biosciences, and Daiichi Sankyo; and grant and/or contract funding from AstraZeneca, Bristol‐Myers Squibb, Roche/Genentech, Amgen, and Mirati. The other authors declare no conflicts of interest.</p></section><section id="notes1"><p>

Synnott D, O’Reilly D, De Freitas D, Naidoo J. Cytokine release syndrome in solid tumors. Cancer. 2025;e70069. doi: 10.1002/cncr.70069

</p></section><section id="cncr70069-sec-0290"><h2 class="pmc_sec_title">DATA AVAILABILITY STATEMENT</h2>
<p>This is a review article. Relevant sources are referenced in article.</p></section><section id="cncr70069-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="cncr70069-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="cncr70069-bib-0001">
<span class="label">1.</span><cite>
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal‐cell carcinoma. N Engl J Med. 2018;378(14):1277‐1290. doi: 10.1056/nejmoa1712126

</cite> [<a href="https://doi.org/10.1056/nejmoa1712126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5972549/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29562145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Nivolumab%20plus%20ipilimumab%20versus%20sunitinib%20in%20advanced%20renal%E2%80%90cell%20carcinoma&amp;author=RJ%20Motzer&amp;author=NM%20Tannir&amp;author=DF%20McDermott&amp;volume=378&amp;issue=14&amp;publication_year=2018&amp;pages=1277-1290&amp;pmid=29562145&amp;doi=10.1056/nejmoa1712126&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0002">
<span class="label">2.</span><cite>
Wolchok JD, Chiarion‐Sileni V, Gonzalez R, et al. Long‐term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127‐137. doi: 10.1200/jco.21.02229

</cite> [<a href="https://doi.org/10.1200/jco.21.02229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8718224/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34818112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Long%E2%80%90term%20outcomes%20with%20nivolumab%20plus%20ipilimumab%20or%20nivolumab%20alone%20versus%20ipilimumab%20in%20patients%20with%20advanced%20melanoma&amp;author=JD%20Wolchok&amp;author=V%20Chiarion%E2%80%90Sileni&amp;author=R%20Gonzalez&amp;volume=40&amp;issue=2&amp;publication_year=2022&amp;pages=127-137&amp;pmid=34818112&amp;doi=10.1200/jco.21.02229&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0003">
<span class="label">3.</span><cite>
Gandhi L, Rodríguez‐Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378(22):2078‐2092. doi: 10.1056/nejmoa1801005

</cite> [<a href="https://doi.org/10.1056/nejmoa1801005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29658856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non%E2%80%90small%E2%80%90cell%20lung%20cancer&amp;author=L%20Gandhi&amp;author=D%20Rodr%C3%ADguez%E2%80%90Abreu&amp;author=S%20Gadgeel&amp;volume=378&amp;issue=22&amp;publication_year=2018&amp;pages=2078-2092&amp;pmid=29658856&amp;doi=10.1056/nejmoa1801005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0004">
<span class="label">4.</span><cite>
Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small‐cell lung cancer. N Engl J Med. 2023;389(22):2063‐2075. doi: 10.1056/nejmoa2307980

</cite> [<a href="https://doi.org/10.1056/nejmoa2307980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37861218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Tarlatamab%20for%20patients%20with%20previously%20treated%20small%E2%80%90cell%20lung%20cancer&amp;author=MJ%20Ahn&amp;author=BC%20Cho&amp;author=E%20Felip&amp;volume=389&amp;issue=22&amp;publication_year=2023&amp;pages=2063-2075&amp;pmid=37861218&amp;doi=10.1056/nejmoa2307980&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0005">
<span class="label">5.</span><cite>
Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196‐1206. doi: 10.1056/nejmoa2103485

</cite> [<a href="https://doi.org/10.1056/nejmoa2103485" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34551229/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Overall%20survival%20benefit%20with%20tebentafusp%20in%20metastatic%20uveal%20melanoma&amp;author=P%20Nathan&amp;author=JC%20Hassel&amp;author=P%20Rutkowski&amp;volume=385&amp;issue=13&amp;publication_year=2021&amp;pages=1196-1206&amp;pmid=34551229&amp;doi=10.1056/nejmoa2103485&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0006">
<span class="label">6.</span><cite>
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel‐T immunotherapy for castration‐resistant prostate cancer. N Engl J Med. 2010;363(5):411‐422. doi: 10.1056/nejmoa1001294

</cite> [<a href="https://doi.org/10.1056/nejmoa1001294" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20818862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Sipuleucel%E2%80%90T%20immunotherapy%20for%20castration%E2%80%90resistant%20prostate%20cancer&amp;author=PW%20Kantoff&amp;author=CS%20Higano&amp;author=ND%20Shore&amp;volume=363&amp;issue=5&amp;publication_year=2010&amp;pages=411-422&amp;pmid=20818862&amp;doi=10.1056/nejmoa1001294&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0007">
<span class="label">7.</span><cite>
National Library of Medicine
. ClinicalTrials.gov Online 2024. Accessed November 11, 2024. <a href="https://clinicaltrials.gov/" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ClinicalTrials.gov/</a>
</cite>
</li>
<li id="cncr70069-bib-0008">
<span class="label">8.</span><cite>
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625‐638. doi: 10.1016/j.bbmt.2018.12.758

</cite> [<a href="https://doi.org/10.1016/j.bbmt.2018.12.758" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12180426/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30592986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Blood%20Marrow%20Transplant&amp;title=ASTCT%20consensus%20grading%20for%20cytokine%20release%20syndrome%20and%20neurologic%20toxicity%20associated%20with%20immune%20effector%20cells&amp;author=DW%20Lee&amp;author=BD%20Santomasso&amp;author=FL%20Locke&amp;volume=25&amp;issue=4&amp;publication_year=2019&amp;pages=625-638&amp;pmid=30592986&amp;doi=10.1016/j.bbmt.2018.12.758&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0009">
<span class="label">9.</span><cite>
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188‐195. doi: 10.1182/blood-2014-05-552729

</cite> [<a href="https://doi.org/10.1182/blood-2014-05-552729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4093680/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24876563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Current%20concepts%20in%20the%20diagnosis%20and%20management%20of%20cytokine%20release%20syndrome&amp;author=DW%20Lee&amp;author=R%20Gardner&amp;author=DL%20Porter&amp;volume=124&amp;issue=2&amp;publication_year=2014&amp;pages=188-195&amp;pmid=24876563&amp;doi=10.1182/blood-2014-05-552729&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0010">
<span class="label">10.</span><cite>
Shimabukuro‐Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi: 10.1186/s40425-018-0343-9

</cite> [<a href="https://doi.org/10.1186/s40425-018-0343-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6003181/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29907163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Cytokine%20release%20syndrome&amp;author=A%20Shimabukuro%E2%80%90Vornhagen&amp;author=P%20G%C3%B6del&amp;author=M%20Subklewe&amp;volume=6&amp;issue=1&amp;publication_year=2018&amp;pages=56&amp;pmid=29907163&amp;doi=10.1186/s40425-018-0343-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0011">
<span class="label">11.</span><cite>
Yáñez L, Sánchez‐Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3(2):e186. doi: 10.1097/hs9.0000000000000186

</cite> [<a href="https://doi.org/10.1097/hs9.0000000000000186" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6746032/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31723825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hemasphere&amp;title=CAR%20T%20cell%20toxicity:%20current%20management%20and%20future%20directions&amp;author=L%20Y%C3%A1%C3%B1ez&amp;author=M%20S%C3%A1nchez%E2%80%90Escamilla&amp;author=MA%20Perales&amp;volume=3&amp;issue=2&amp;publication_year=2019&amp;pages=e186&amp;pmid=31723825&amp;doi=10.1097/hs9.0000000000000186&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0012">
<span class="label">12.</span><cite>
Guha P, Heatherton KR, O'Connell KP, Alexander IS, Katz SC. Assessing the future of solid tumor immunotherapy. Biomedicines. 2022;10(3):655. doi: 10.3390/biomedicines10030655

</cite> [<a href="https://doi.org/10.3390/biomedicines10030655" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8945484/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35327456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=Assessing%20the%20future%20of%20solid%20tumor%20immunotherapy&amp;author=P%20Guha&amp;author=KR%20Heatherton&amp;author=KP%20O'Connell&amp;author=IS%20Alexander&amp;author=SC%20Katz&amp;volume=10&amp;issue=3&amp;publication_year=2022&amp;pages=655&amp;pmid=35327456&amp;doi=10.3390/biomedicines10030655&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0013">
<span class="label">13.</span><cite>
Zhang Y, Wen X, OuYang Y, et al. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients ‐ a case report and review of the literature. Heliyon. 2024;10(2):e24380. doi: 10.1016/j.heliyon.2024.e243802

</cite> [<a href="https://doi.org/10.1016/j.heliyon.2024.e243802" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10826737/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38293388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heliyon&amp;title=Severe%20cytokine%20release%20syndrome%20induced%20by%20immune%20checkpoint%20inhibitors%20in%20cancer%20patients%20%E2%80%90%20a%20case%20report%20and%20review%20of%20the%20literature&amp;author=Y%20Zhang&amp;author=X%20Wen&amp;author=Y%20OuYang&amp;volume=10&amp;issue=2&amp;publication_year=2024&amp;pages=e24380&amp;pmid=38293388&amp;doi=10.1016/j.heliyon.2024.e243802&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0014">
<span class="label">14.</span><cite>
Menakuru SR, Azeem Q, Priscu A, Khan I, Beirat A. Stage 4 cytokine release syndrome caused by the first dose of nivolumab and ipilimumab combination therapy in a patient with metastatic melanoma successfully treated with methylprednisolone, tocilizumab, and etanercept. Case Rep Oncol. 2022;15(2):648‐653. doi: 10.1159/000525173

</cite> [<a href="https://doi.org/10.1159/000525173" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9294929/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35949898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Case%20Rep%20Oncol&amp;title=Stage%204%20cytokine%20release%20syndrome%20caused%20by%20the%20first%20dose%20of%20nivolumab%20and%20ipilimumab%20combination%20therapy%20in%20a%20patient%20with%20metastatic%20melanoma%20successfully%20treated%20with%20methylprednisolone,%20tocilizumab,%20and%20etanercept&amp;author=SR%20Menakuru&amp;author=Q%20Azeem&amp;author=A%20Priscu&amp;author=I%20Khan&amp;author=A%20Beirat&amp;volume=15&amp;issue=2&amp;publication_year=2022&amp;pages=648-653&amp;pmid=35949898&amp;doi=10.1159/000525173&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0015">
<span class="label">15.</span><cite>
Hassel JC, Piperno‐Neumann S, Rutkowski P, et al. Three‐year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256‐2266. doi: 10.1056/nejmoa2304753

</cite> [<a href="https://doi.org/10.1056/nejmoa2304753" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11188986/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37870955/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Three%E2%80%90year%20overall%20survival%20with%20tebentafusp%20in%20metastatic%20uveal%20melanoma&amp;author=JC%20Hassel&amp;author=S%20Piperno%E2%80%90Neumann&amp;author=P%20Rutkowski&amp;volume=389&amp;issue=24&amp;publication_year=2023&amp;pages=2256-2266&amp;pmid=37870955&amp;doi=10.1056/nejmoa2304753&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0016">
<span class="label">16.</span><cite>
Ramani T, Auletta CS, Weinstock D, et al. Cytokines: the good, the bad, and the deadly. Int J Toxicol. 2015;34(4):355‐365. doi: 10.1177/1091581815584918

</cite> [<a href="https://doi.org/10.1177/1091581815584918" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26015504/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Toxicol&amp;title=Cytokines:%20the%20good,%20the%20bad,%20and%20the%20deadly&amp;author=T%20Ramani&amp;author=CS%20Auletta&amp;author=D%20Weinstock&amp;volume=34&amp;issue=4&amp;publication_year=2015&amp;pages=355-365&amp;pmid=26015504&amp;doi=10.1177/1091581815584918&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0017">
<span class="label">17.</span><cite>
Lefkowitz DL, Lefkowitz SS. Macrophage‐neutrophil interaction: a paradigm for chronic inflammation revisited. Immunol Cell Biol. 2001;79(5):502‐506. doi: 10.1046/j.1440-1711.2001.01020.x

</cite> [<a href="https://doi.org/10.1046/j.1440-1711.2001.01020.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11564158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunol%20Cell%20Biol&amp;title=Macrophage%E2%80%90neutrophil%20interaction:%20a%20paradigm%20for%20chronic%20inflammation%20revisited&amp;author=DL%20Lefkowitz&amp;author=SS%20Lefkowitz&amp;volume=79&amp;issue=5&amp;publication_year=2001&amp;pages=502-506&amp;pmid=11564158&amp;doi=10.1046/j.1440-1711.2001.01020.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0018">
<span class="label">18.</span><cite>
Stenken JA, Poschenrieder AJ. Bioanalytical chemistry of cytokines‐‐a review. Anal Chim Acta. 2015;853:95‐115. doi: 10.1016/j.aca.2014.10.009

</cite> [<a href="https://doi.org/10.1016/j.aca.2014.10.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4717841/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25467452/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anal%20Chim%20Acta&amp;title=Bioanalytical%20chemistry%20of%20cytokines%E2%80%90%E2%80%90a%20review&amp;author=JA%20Stenken&amp;author=AJ%20Poschenrieder&amp;volume=853&amp;publication_year=2015&amp;pages=95-115&amp;pmid=25467452&amp;doi=10.1016/j.aca.2014.10.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0019">
<span class="label">19.</span><cite>
Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti‐T‐cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon‐gamma [corrected]. N Engl J Med. 1989;320(21):1420‐1421. doi: 10.1056/NEJM198905253202117

</cite> [<a href="https://doi.org/10.1056/NEJM198905253202117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2785642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Systemic%20reaction%20to%20the%20anti%E2%80%90T%E2%80%90cell%20monoclonal%20antibody%20OKT3%20in%20relation%20to%20serum%20levels%20of%20tumor%20necrosis%20factor%20and%20interferon%E2%80%90gamma%20%5Bcorrected%5D&amp;author=L%20Chatenoud&amp;author=C%20Ferran&amp;author=A%20Reuter&amp;volume=320&amp;issue=21&amp;publication_year=1989&amp;pages=1420-1421&amp;pmid=2785642&amp;doi=10.1056/NEJM198905253202117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0020">
<span class="label">20.</span><cite>
Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 1990;49(4):697‐702. doi: 10.1097/00007890-199004000-00009

</cite> [<a href="https://doi.org/10.1097/00007890-199004000-00009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2109379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&amp;title=In%20vivo%20cell%20activation%20following%20OKT3%20administration.%20Systemic%20cytokine%20release%20and%20modulation%20by%20corticosteroids&amp;author=L%20Chatenoud&amp;author=C%20Ferran&amp;author=C%20Legendre&amp;volume=49&amp;issue=4&amp;publication_year=1990&amp;pages=697-702&amp;pmid=2109379&amp;doi=10.1097/00007890-199004000-00009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0021">
<span class="label">21.</span><cite>
Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy. Pediatr Blood Cancer. 2017;64(12):e26642. doi: 10.1002/pbc.26642
</cite> [<a href="https://doi.org/10.1002/pbc.26642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28544595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pediatr%20Blood%20Cancer&amp;title=Severe%20cytokine%20release%20syndrome%20in%20a%20patient%20receiving%20PD%E2%80%901%E2%80%90directed%20therapy&amp;author=SJ%20Rotz&amp;author=D%20Leino&amp;author=S%20Szabo&amp;author=JL%20Mangino&amp;author=BK%20Turpin&amp;volume=64&amp;issue=12&amp;publication_year=2017&amp;pages=e26642&amp;pmid=28544595&amp;doi=10.1002/pbc.26642&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0022">
<span class="label">22.</span><cite>
Pihusch R, Holler E, Mühlbayer D, et al. The impact of antithymocyte globulin on short‐term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(6):347‐354. doi: 10.1038/sj.bmt.1703640

</cite> [<a href="https://doi.org/10.1038/sj.bmt.1703640" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12235518/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bone%20Marrow%20Transplant&amp;title=The%20impact%20of%20antithymocyte%20globulin%20on%20short%E2%80%90term%20toxicity%20after%20allogeneic%20stem%20cell%20transplantation&amp;author=R%20Pihusch&amp;author=E%20Holler&amp;author=D%20M%C3%BChlbayer&amp;volume=30&amp;issue=6&amp;publication_year=2002&amp;pages=347-354&amp;pmid=12235518&amp;doi=10.1038/sj.bmt.1703640&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0023">
<span class="label">23.</span><cite>
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine‐release syndrome in patients with B‐cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti‐CD20 monoclonal antibody (rituximab, IDEC‐C2B8). Blood. 1999;94(7):2217‐2224. doi: 10.1182/blood.v94.7.2217.419k02_2217_2224

</cite> [<a href="https://doi.org/10.1182/blood.v94.7.2217.419k02_2217_2224" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10498591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Cytokine%E2%80%90release%20syndrome%20in%20patients%20with%20B%E2%80%90cell%20chronic%20lymphocytic%20leukemia%20and%20high%20lymphocyte%20counts%20after%20treatment%20with%20an%20anti%E2%80%90CD20%20monoclonal%20antibody%20(rituximab,%20IDEC%E2%80%90C2B8)&amp;author=U%20Winkler&amp;author=M%20Jensen&amp;author=O%20Manzke&amp;author=H%20Schulz&amp;author=V%20Diehl&amp;volume=94&amp;issue=7&amp;publication_year=1999&amp;pages=2217-2224&amp;pmid=10498591&amp;doi=10.1182/blood.v94.7.2217.419k02_2217_2224&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0024">
<span class="label">24.</span><cite>
Freeman CL, Morschhauser F, Sehn L, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion‐related reactions. Blood. 2015;126(24):2646‐2649. doi: 10.1182/blood-2015-09-670802

</cite> [<a href="https://doi.org/10.1182/blood-2015-09-670802" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4671111/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26447188/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Cytokine%20release%20in%20patients%20with%20CLL%20treated%20with%20obinutuzumab%20and%20possible%20relationship%20with%20infusion%E2%80%90related%20reactions&amp;author=CL%20Freeman&amp;author=F%20Morschhauser&amp;author=L%20Sehn&amp;volume=126&amp;issue=24&amp;publication_year=2015&amp;pages=2646-2649&amp;pmid=26447188&amp;doi=10.1182/blood-2015-09-670802&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0025">
<span class="label">25.</span><cite>
Wing MG, Moreau T, Greenwood J, et al. Mechanism of first‐dose cytokine‐release syndrome by CAMPATH 1‐H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA‐1) on NK cells. J Clin Investig. 1996;98(12):2819‐2826. doi: 10.1172/jci119110

</cite> [<a href="https://doi.org/10.1172/jci119110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC507749/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8981930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Investig&amp;title=Mechanism%20of%20first%E2%80%90dose%20cytokine%E2%80%90release%20syndrome%20by%20CAMPATH%201%E2%80%90H:%20involvement%20of%20CD16%20(FcgammaRIII)%20and%20CD11a/CD18%20(LFA%E2%80%901)%20on%20NK%20cells&amp;author=MG%20Wing&amp;author=T%20Moreau&amp;author=J%20Greenwood&amp;volume=98&amp;issue=12&amp;publication_year=1996&amp;pages=2819-2826&amp;pmid=8981930&amp;doi=10.1172/jci119110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0026">
<span class="label">26.</span><cite>
Alig SK, Dreyling M, Seppi B, Aulinger B, Witkowski L, Rieger CT. Severe cytokine release syndrome after the first dose of brentuximab vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature. Eur J Haematol. 2015;94(6):554‐557. doi: 10.1111/ejh.12396

</cite> [<a href="https://doi.org/10.1111/ejh.12396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24913471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Haematol&amp;title=Severe%20cytokine%20release%20syndrome%20after%20the%20first%20dose%20of%20brentuximab%20vedotin%20in%20a%20patient%20with%20relapsed%20systemic%20anaplastic%20large%20cell%20lymphoma%20(sALCL):%20a%20case%20report%20and%20review%20of%20literature&amp;author=SK%20Alig&amp;author=M%20Dreyling&amp;author=B%20Seppi&amp;author=B%20Aulinger&amp;author=L%20Witkowski&amp;volume=94&amp;issue=6&amp;publication_year=2015&amp;pages=554-557&amp;pmid=24913471&amp;doi=10.1111/ejh.12396&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0027">
<span class="label">27.</span><cite>
de Vos S, Forero‐Torres A, Ansell SM, et al. A phase II study of dacetuzumab (SGN‐40) in patients with relapsed diffuse large B‐cell lymphoma (DLBCL) and correlative analyses of patient‐specific factors. J Hematol Oncol. 2014;7(1):44. doi: 10.1186/1756-8722-7-44

</cite> [<a href="https://doi.org/10.1186/1756-8722-7-44" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4065310/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24919462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=A%20phase%20II%20study%20of%20dacetuzumab%20(SGN%E2%80%9040)%20in%20patients%20with%20relapsed%20diffuse%20large%20B%E2%80%90cell%20lymphoma%20(DLBCL)%20and%20correlative%20analyses%20of%20patient%E2%80%90specific%20factors&amp;author=S%20de%20Vos&amp;author=A%20Forero%E2%80%90Torres&amp;author=SM%20Ansell&amp;volume=7&amp;issue=1&amp;publication_year=2014&amp;pages=44&amp;pmid=24919462&amp;doi=10.1186/1756-8722-7-44&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0028">
<span class="label">28.</span><cite>
Moore JB, June CH. Cytokine release syndrome in severe COVID‐19. Science. 2020;368(6490):473‐474. doi: 10.1126/science.abb8925

</cite> [<a href="https://doi.org/10.1126/science.abb8925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32303591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Cytokine%20release%20syndrome%20in%20severe%20COVID%E2%80%9019&amp;author=JB%20Moore&amp;author=CH%20June&amp;volume=368&amp;issue=6490&amp;publication_year=2020&amp;pages=473-474&amp;pmid=32303591&amp;doi=10.1126/science.abb8925&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0029">
<span class="label">29.</span><cite>
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16‐32. doi: 10.1128/mmbr.05015-11

</cite> [<a href="https://doi.org/10.1128/mmbr.05015-11" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3294426/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22390970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microbiol%20Mol%20Biol%20Rev&amp;title=Into%20the%20eye%20of%20the%20cytokine%20storm&amp;author=JR%20Tisoncik&amp;author=MJ%20Korth&amp;author=CP%20Simmons&amp;author=J%20Farrar&amp;author=TR%20Martin&amp;volume=76&amp;issue=1&amp;publication_year=2012&amp;pages=16-32&amp;pmid=22390970&amp;doi=10.1128/mmbr.05015-11&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0030">
<span class="label">30.</span><cite>
Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85‐96. doi: 10.1038/s41577-021-00547-6

</cite> [<a href="https://doi.org/10.1038/s41577-021-00547-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8127450/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34002066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Immunol&amp;title=Cytokine%20release%20syndrome%20and%20associated%20neurotoxicity%20in%20cancer%20immunotherapy&amp;author=EC%20Morris&amp;author=SS%20Neelapu&amp;author=T%20Giavridis&amp;author=M%20Sadelain&amp;volume=22&amp;issue=2&amp;publication_year=2022&amp;pages=85-96&amp;pmid=34002066&amp;doi=10.1038/s41577-021-00547-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0031">
<span class="label">31.</span><cite>
Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T‐cell‐based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021;22(14):7652. doi: 10.3390/ijms22147652

</cite> [<a href="https://doi.org/10.3390/ijms22147652" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8305850/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34299273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Cytokine%20release%20syndrome%20associated%20with%20T%E2%80%90cell%E2%80%90based%20therapies%20for%20hematological%20malignancies:%20pathophysiology,%20clinical%20presentation,%20and%20treatment&amp;author=M%20Cosenza&amp;author=S%20Sacchi&amp;author=S%20Pozzi&amp;volume=22&amp;issue=14&amp;publication_year=2021&amp;pages=7652&amp;pmid=34299273&amp;doi=10.3390/ijms22147652&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0032">
<span class="label">32.</span><cite>
Liu E, Marin D, Banerjee P, et al. Use of CAR‐transduced natural killer cells in CD19‐positive lymphoid tumors. N Engl J Med. 2020;382(6):545‐553. doi: 10.1056/nejmoa1910607

</cite> [<a href="https://doi.org/10.1056/nejmoa1910607" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7101242/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32023374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Use%20of%20CAR%E2%80%90transduced%20natural%20killer%20cells%20in%20CD19%E2%80%90positive%20lymphoid%20tumors&amp;author=E%20Liu&amp;author=D%20Marin&amp;author=P%20Banerjee&amp;volume=382&amp;issue=6&amp;publication_year=2020&amp;pages=545-553&amp;pmid=32023374&amp;doi=10.1056/nejmoa1910607&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0033">
<span class="label">33.</span><cite>
Nieto Y, Banerjee P, Kaur I, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025;31(6):1987‐1993. doi: 10.1038/s41591-025-03640-8

</cite> [<a href="https://doi.org/10.1038/s41591-025-03640-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40186077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Allogeneic%20NK%20cells%20with%20a%20bispecific%20innate%20cell%20engager%20in%20refractory%20relapsed%20lymphoma:%20a%20phase%201%20trial&amp;author=Y%20Nieto&amp;author=P%20Banerjee&amp;author=I%20Kaur&amp;volume=31&amp;issue=6&amp;publication_year=2025&amp;pages=1987-1993&amp;pmid=40186077&amp;doi=10.1038/s41591-025-03640-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0034">
<span class="label">34.</span><cite>
Sterner RM, Sakemura R, Cox MJ, et al. GM‐CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR‐T cell function in xenografts. Blood. 2019;133(7):697‐709. doi: 10.1182/blood-2018-10-881722

</cite> [<a href="https://doi.org/10.1182/blood-2018-10-881722" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6376281/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30463995/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=GM%E2%80%90CSF%20inhibition%20reduces%20cytokine%20release%20syndrome%20and%20neuroinflammation%20but%20enhances%20CAR%E2%80%90T%20cell%20function%20in%20xenografts&amp;author=RM%20Sterner&amp;author=R%20Sakemura&amp;author=MJ%20Cox&amp;volume=133&amp;issue=7&amp;publication_year=2019&amp;pages=697-709&amp;pmid=30463995&amp;doi=10.1182/blood-2018-10-881722&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0035">
<span class="label">35.</span><cite>
Matthys P, Dillen C, Proost P, Heremans H, Van Damme J, Billiau A. Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐gamma or anti‐interleukin‐6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol. 1993;23(9):2209‐2216. doi: 10.1002/eji.1830230924

</cite> [<a href="https://doi.org/10.1002/eji.1830230924" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8370401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Immunol&amp;title=Modification%20of%20the%20anti%E2%80%90CD3%E2%80%90induced%20cytokine%20release%20syndrome%20by%20anti%E2%80%90interferon%E2%80%90gamma%20or%20anti%E2%80%90interleukin%E2%80%906%20antibody%20treatment:%20protective%20effects%20and%20biphasic%20changes%20in%20blood%20cytokine%20levels&amp;author=P%20Matthys&amp;author=C%20Dillen&amp;author=P%20Proost&amp;author=H%20Heremans&amp;author=J%20Van%20Damme&amp;volume=23&amp;issue=9&amp;publication_year=1993&amp;pages=2209-2216&amp;pmid=8370401&amp;doi=10.1002/eji.1830230924&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0036">
<span class="label">36.</span><cite>
Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR‐T cell therapy. Biomark Res. 2018;6(1):4. doi: 10.1186/s40364-018-0116-0

</cite> [<a href="https://doi.org/10.1186/s40364-018-0116-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5778792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29387417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomark%20Res&amp;title=Biomarkers%20of%20cytokine%20release%20syndrome%20and%20neurotoxicity%20related%20to%20CAR%E2%80%90T%20cell%20therapy&amp;author=Z%20Wang&amp;author=W%20Han&amp;volume=6&amp;issue=1&amp;publication_year=2018&amp;pages=4&amp;pmid=29387417&amp;doi=10.1186/s40364-018-0116-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0037">
<span class="label">37.</span><cite>
Norelli M, Camisa B, Barbiera G, et al. Monocyte‐derived IL‐1 and IL‐6 are differentially required for cytokine‐release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739‐748. doi: 10.1038/s41591-018-0036-4

</cite> [<a href="https://doi.org/10.1038/s41591-018-0036-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29808007/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Monocyte%E2%80%90derived%20IL%E2%80%901%20and%20IL%E2%80%906%20are%20differentially%20required%20for%20cytokine%E2%80%90release%20syndrome%20and%20neurotoxicity%20due%20to%20CAR%20T%20cells&amp;author=M%20Norelli&amp;author=B%20Camisa&amp;author=G%20Barbiera&amp;volume=24&amp;issue=6&amp;publication_year=2018&amp;pages=739-748&amp;pmid=29808007&amp;doi=10.1038/s41591-018-0036-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0038">
<span class="label">38.</span><cite>
Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL‐6) immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(8):a028456. doi: 10.1101/cshperspect.a028456

</cite> [<a href="https://doi.org/10.1101/cshperspect.a028456" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6071487/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28778870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cold%20Spring%20Harb%20Perspect%20Biol&amp;title=Interleukin%20(IL%E2%80%906)%20immunotherapy&amp;author=T%20Tanaka&amp;author=M%20Narazaki&amp;author=T%20Kishimoto&amp;volume=10&amp;issue=8&amp;publication_year=2018&amp;pages=a028456&amp;pmid=28778870&amp;doi=10.1101/cshperspect.a028456&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0039">
<span class="label">39.</span><cite>
Del Giudice M, Gangestad SW. Rethinking IL‐6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61‐75. doi: 10.1016/j.bbi.2018.02.013

</cite> [<a href="https://doi.org/10.1016/j.bbi.2018.02.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29499302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Behav%20Immun&amp;title=Rethinking%20IL%E2%80%906%20and%20CRP:%20why%20they%20are%20more%20than%20inflammatory%20biomarkers,%20and%20why%20it%20matters&amp;author=M%20Del%20Giudice&amp;author=SW%20Gangestad&amp;volume=70&amp;publication_year=2018&amp;pages=61-75&amp;pmid=29499302&amp;doi=10.1016/j.bbi.2018.02.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0040">
<span class="label">40.</span><cite>
Rose‐John S. IL‐6 trans‐signaling via the soluble IL‐6 receptor: importance for the pro‐inflammatory activities of IL‐6. Int J Biol Sci. 2012;8(9):1237‐1247. doi: 10.7150/ijbs.4989

</cite> [<a href="https://doi.org/10.7150/ijbs.4989" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3491447/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23136552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Biol%20Sci&amp;title=IL%E2%80%906%20trans%E2%80%90signaling%20via%20the%20soluble%20IL%E2%80%906%20receptor:%20importance%20for%20the%20pro%E2%80%90inflammatory%20activities%20of%20IL%E2%80%906&amp;author=S%20Rose%E2%80%90John&amp;volume=8&amp;issue=9&amp;publication_year=2012&amp;pages=1237-1247&amp;pmid=23136552&amp;doi=10.7150/ijbs.4989&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0041">
<span class="label">41.</span><cite>
Scheller J, Chalaris A, Schmidt‐Arras D, Rose‐John S. The pro‐ and anti‐inflammatory properties of the cytokine interleukin‐6. Biochim Biophys Acta. 2011;1813(5):878‐888. doi: 10.1016/j.bbamcr.2011.01.034

</cite> [<a href="https://doi.org/10.1016/j.bbamcr.2011.01.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21296109/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochim%20Biophys%20Acta&amp;title=The%20pro%E2%80%90%20and%20anti%E2%80%90inflammatory%20properties%20of%20the%20cytokine%20interleukin%E2%80%906&amp;author=J%20Scheller&amp;author=A%20Chalaris&amp;author=D%20Schmidt%E2%80%90Arras&amp;author=S%20Rose%E2%80%90John&amp;volume=1813&amp;issue=5&amp;publication_year=2011&amp;pages=878-888&amp;pmid=21296109&amp;doi=10.1016/j.bbamcr.2011.01.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0042">
<span class="label">42.</span><cite>
Jones SA, Scheller J, Rose‐John S. Therapeutic strategies for the clinical blockade of IL‐6/gp130 signaling. J Clin Investig. 2011;121(9):3375‐3383. doi: 10.1172/jci57158

</cite> [<a href="https://doi.org/10.1172/jci57158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3163962/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21881215/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Investig&amp;title=Therapeutic%20strategies%20for%20the%20clinical%20blockade%20of%20IL%E2%80%906/gp130%20signaling&amp;author=SA%20Jones&amp;author=J%20Scheller&amp;author=S%20Rose%E2%80%90John&amp;volume=121&amp;issue=9&amp;publication_year=2011&amp;pages=3375-3383&amp;pmid=21881215&amp;doi=10.1172/jci57158&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0043">
<span class="label">43.</span><cite>
Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL‐6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959‐970. doi: 10.2217/imt-2016-0020

</cite> [<a href="https://doi.org/10.2217/imt-2016-0020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27381687/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunotherapy&amp;title=Immunotherapeutic%20implications%20of%20IL%E2%80%906%20blockade%20for%20cytokine%20storm&amp;author=T%20Tanaka&amp;author=M%20Narazaki&amp;author=T%20Kishimoto&amp;volume=8&amp;issue=8&amp;publication_year=2016&amp;pages=959-970&amp;pmid=27381687&amp;doi=10.2217/imt-2016-0020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0044">
<span class="label">44.</span><cite>
Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor‐related cytokine release syndrome: analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020;11:557. doi: 10.3389/fphar.2020.00557

</cite> [<a href="https://doi.org/10.3389/fphar.2020.00557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7212758/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32425791/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Immune%20checkpoint%20inhibitor%E2%80%90related%20cytokine%20release%20syndrome:%20analysis%20of%20WHO%20Global%20Pharmacovigilance%20Database&amp;author=A%20Ceschi&amp;author=R%20Noseda&amp;author=K%20Palin&amp;author=K%20Verhamme&amp;volume=11&amp;publication_year=2020&amp;pages=557&amp;pmid=32425791&amp;doi=10.3389/fphar.2020.00557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0045">
<span class="label">45.</span><cite>
Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin‐6 (IL‐6) gene on IL‐6 transcription and plasma IL‐6 levels, and an association with systemic‐onset juvenile chronic arthritis. J Clin Investig. 1998;102(7):1369‐1376. doi: 10.1172/jci2629

</cite> [<a href="https://doi.org/10.1172/jci2629" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC508984/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9769329/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Investig&amp;title=The%20effect%20of%20novel%20polymorphisms%20in%20the%20interleukin%E2%80%906%20(IL%E2%80%906)%20gene%20on%20IL%E2%80%906%20transcription%20and%20plasma%20IL%E2%80%906%20levels,%20and%20an%20association%20with%20systemic%E2%80%90onset%20juvenile%20chronic%20arthritis&amp;author=D%20Fishman&amp;author=G%20Faulds&amp;author=R%20Jeffery&amp;volume=102&amp;issue=7&amp;publication_year=1998&amp;pages=1369-1376&amp;pmid=9769329&amp;doi=10.1172/jci2629&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0046">
<span class="label">46.</span><cite>
Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7(10):803‐815. doi: 10.1038/nri2171

</cite> [<a href="https://doi.org/10.1038/nri2171" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17893694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Immunol&amp;title=Evolving%20functions%20of%20endothelial%20cells%20in%20inflammation&amp;author=JS%20Pober&amp;author=WC%20Sessa&amp;volume=7&amp;issue=10&amp;publication_year=2007&amp;pages=803-815&amp;pmid=17893694&amp;doi=10.1038/nri2171&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0047">
<span class="label">47.</span><cite>
Obstfeld AE, Frey NV, Mansfield K, et al. Cytokine release syndrome associated with chimeric‐antigen receptor T‐cell therapy: clinicopathological insights. Blood. 2017;130(23):2569‐2572. doi: 10.1182/blood-2017-08-802413

</cite> [<a href="https://doi.org/10.1182/blood-2017-08-802413" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29074500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Cytokine%20release%20syndrome%20associated%20with%20chimeric%E2%80%90antigen%20receptor%20T%E2%80%90cell%20therapy:%20clinicopathological%20insights&amp;author=AE%20Obstfeld&amp;author=NV%20Frey&amp;author=K%20Mansfield&amp;volume=130&amp;issue=23&amp;publication_year=2017&amp;pages=2569-2572&amp;pmid=29074500&amp;doi=10.1182/blood-2017-08-802413&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0048">
<span class="label">48.</span><cite>
Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor‐modified T‐cell therapy. Blood. 2017;130(21):2295‐2306. doi: 10.1182/blood-2017-06-793141

</cite> [<a href="https://doi.org/10.1182/blood-2017-06-793141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5701525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28924019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Kinetics%20and%20biomarkers%20of%20severe%20cytokine%20release%20syndrome%20after%20CD19%20chimeric%20antigen%20receptor%E2%80%90modified%20T%E2%80%90cell%20therapy&amp;author=KA%20Hay&amp;author=LA%20Hanafi&amp;author=D%20Li&amp;volume=130&amp;issue=21&amp;publication_year=2017&amp;pages=2295-2306&amp;pmid=28924019&amp;doi=10.1182/blood-2017-06-793141&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0049">
<span class="label">49.</span><cite>
Kang S, Tanaka T, Inoue H, et al. IL‐6 trans‐signaling induces plasminogen activator inhibitor‐1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA. 2020;117(36):22351‐22356. doi: 10.1073/pnas.2010229117

</cite> [<a href="https://doi.org/10.1073/pnas.2010229117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7486751/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32826331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20USA&amp;title=IL%E2%80%906%20trans%E2%80%90signaling%20induces%20plasminogen%20activator%20inhibitor%E2%80%901%20from%20vascular%20endothelial%20cells%20in%20cytokine%20release%20syndrome&amp;author=S%20Kang&amp;author=T%20Tanaka&amp;author=H%20Inoue&amp;volume=117&amp;issue=36&amp;publication_year=2020&amp;pages=22351-22356&amp;pmid=32826331&amp;doi=10.1073/pnas.2010229117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0050">
<span class="label">50.</span><cite>
Galli E, Sorà F, Hohaus S, et al. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti‐CD19 CAR‐T cells. Br J Haematol. 2023;201(1):86‐94. doi: 10.1111/bjh.18596

</cite> [<a href="https://doi.org/10.1111/bjh.18596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36503182/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Haematol&amp;title=Endothelial%20activation%20predicts%20disseminated%20intravascular%20coagulopathy,%20cytokine%20release%20syndrome%20and%20prognosis%20in%20patients%20treated%20with%20anti%E2%80%90CD19%20CAR%E2%80%90T%20cells&amp;author=E%20Galli&amp;author=F%20Sor%C3%A0&amp;author=S%20Hohaus&amp;volume=201&amp;issue=1&amp;publication_year=2023&amp;pages=86-94&amp;pmid=36503182&amp;doi=10.1111/bjh.18596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0051">
<span class="label">51.</span><cite>
Rojas‐Quintero J, Díaz MP, Palmar J, et al. Car T cells in solid tumors: overcoming obstacles. Int J Mol Sci. 2024;25(8):4170. doi: 10.3390/ijms25084170

</cite> [<a href="https://doi.org/10.3390/ijms25084170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11050550/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38673757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Car%20T%20cells%20in%20solid%20tumors:%20overcoming%20obstacles&amp;author=J%20Rojas%E2%80%90Quintero&amp;author=MP%20D%C3%ADaz&amp;author=J%20Palmar&amp;volume=25&amp;issue=8&amp;publication_year=2024&amp;pages=4170&amp;pmid=38673757&amp;doi=10.3390/ijms25084170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0052">
<span class="label">52.</span><cite>
Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126‐133. doi: 10.1016/j.canlet.2019.11.009

</cite> [<a href="https://doi.org/10.1016/j.canlet.2019.11.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31730903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett&amp;title=Immune%20cells%20within%20the%20tumor%20microenvironment:%20biological%20functions%20and%20roles%20in%20cancer%20immunotherapy&amp;author=X%20Lei&amp;author=Y%20Lei&amp;author=JK%20Li&amp;volume=470&amp;publication_year=2020&amp;pages=126-133&amp;pmid=31730903&amp;doi=10.1016/j.canlet.2019.11.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0053">
<span class="label">53.</span><cite>
Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761‐773. doi: 10.7150/jca.17648

</cite> [<a href="https://doi.org/10.7150/jca.17648" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5381164/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28382138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cancer&amp;title=Role%20of%20tumor%20microenvironment%20in%20tumorigenesis&amp;author=M%20Wang&amp;author=J%20Zhao&amp;author=L%20Zhang&amp;volume=8&amp;issue=5&amp;publication_year=2017&amp;pages=761-773&amp;pmid=28382138&amp;doi=10.7150/jca.17648&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0054">
<span class="label">54.</span><cite>
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904‐5912. doi: 10.1038/onc.2008.271

</cite> [<a href="https://doi.org/10.1038/onc.2008.271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3689267/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18836471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The%20tumor%20microenvironment%20and%20its%20role%20in%20promoting%20tumor%20growth&amp;author=TL%20Whiteside&amp;volume=27&amp;issue=45&amp;publication_year=2008&amp;pages=5904-5912&amp;pmid=18836471&amp;doi=10.1038/onc.2008.271&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0055">
<span class="label">55.</span><cite>
Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett. 2014;159(1‐2):55‐72. doi: 10.1016/j.imlet.2014.03.001

</cite> [<a href="https://doi.org/10.1016/j.imlet.2014.03.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24657523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunol%20Lett&amp;title=Mechanisms%20of%20tumor%20escape%20from%20immune%20system:%20role%20of%20mesenchymal%20stromal%20cells&amp;author=A%20Poggi&amp;author=A%20Musso&amp;author=I%20Dapino&amp;author=MR%20Zocchi&amp;volume=159&amp;issue=1%E2%80%902&amp;publication_year=2014&amp;pages=55-72&amp;pmid=24657523&amp;doi=10.1016/j.imlet.2014.03.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0056">
<span class="label">56.</span><cite>
Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071‐1121. doi: 10.1152/physrev.00038.2010

</cite> [<a href="https://doi.org/10.1152/physrev.00038.2010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3258432/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21742796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Physiol%20Rev&amp;title=Normalization%20of%20the%20vasculature%20for%20treatment%20of%20cancer%20and%20other%20diseases&amp;author=S%20Goel&amp;author=DG%20Duda&amp;author=L%20Xu&amp;volume=91&amp;issue=3&amp;publication_year=2011&amp;pages=1071-1121&amp;pmid=21742796&amp;doi=10.1152/physrev.00038.2010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0057">
<span class="label">57.</span><cite>
Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the antigen density requirement for CAR T‐cell activity. Cancer Discov. 2020;10(5):702‐723. doi: 10.1158/2159-8290.cd-19-0945

</cite> [<a href="https://doi.org/10.1158/2159-8290.cd-19-0945" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7939454/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32193224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Tuning%20the%20antigen%20density%20requirement%20for%20CAR%20T%E2%80%90cell%20activity&amp;author=RG%20Majzner&amp;author=SP%20Rietberg&amp;author=E%20Sotillo&amp;volume=10&amp;issue=5&amp;publication_year=2020&amp;pages=702-723&amp;pmid=32193224&amp;doi=10.1158/2159-8290.cd-19-0945&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0058">
<span class="label">58.</span><cite>
Van De Vyver AJ, Marrer‐Berger E, Wang K, Lehr T, Walz AC. Cytokine release syndrome by T‐cell‐redirecting therapies: can we predict and modulate patient risk?
Clin Cancer Res. 2021;27(22):6083‐6094. doi: 10.1158/1078-0432.ccr-21-0470

</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-21-0470" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34162679/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Cytokine%20release%20syndrome%20by%20T%E2%80%90cell%E2%80%90redirecting%20therapies:%20can%20we%20predict%20and%20modulate%20patient%20risk?&amp;author=AJ%20Van%20De%20Vyver&amp;author=E%20Marrer%E2%80%90Berger&amp;author=K%20Wang&amp;author=T%20Lehr&amp;author=AC%20Walz&amp;volume=27&amp;issue=22&amp;publication_year=2021&amp;pages=6083-6094&amp;pmid=34162679&amp;doi=10.1158/1078-0432.ccr-21-0470&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0059">
<span class="label">59.</span><cite>
Mau‐Sørensen M, Dittrich C, Dienstmann R, et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol. 2015;75(5):1065‐1073. doi: 10.1007/s00280-015-2728-5

</cite> [<a href="https://doi.org/10.1007/s00280-015-2728-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25814216/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemother%20Pharmacol&amp;title=A%20phase%20I%20trial%20of%20intravenous%20catumaxomab:%20a%20bispecific%20monoclonal%20antibody%20targeting%20EpCAM%20and%20the%20T%20cell%20coreceptor%20CD3&amp;author=M%20Mau%E2%80%90S%C3%B8rensen&amp;author=C%20Dittrich&amp;author=R%20Dienstmann&amp;volume=75&amp;issue=5&amp;publication_year=2015&amp;pages=1065-1073&amp;pmid=25814216&amp;doi=10.1007/s00280-015-2728-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0060">
<span class="label">60.</span><cite>
Middleton MR, McAlpine C, Woodcock VK, et al. A TCR/anti‐CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869‐5878. doi: 10.1158/1078-0432.ccr-20-1247

</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-20-1247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9210997/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32816891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=A%20TCR/anti%E2%80%90CD3%20bispecific%20fusion%20protein%20targeting%20gp100,%20potently%20activated%20antitumor%20immune%20responses%20in%20patients%20with%20metastatic%20melanoma&amp;author=MR%20Middleton&amp;author=C%20McAlpine&amp;author=VK%20Woodcock&amp;volume=26&amp;issue=22&amp;publication_year=2020&amp;pages=5869-5878&amp;pmid=32816891&amp;doi=10.1158/1078-0432.ccr-20-1247&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0061">
<span class="label">61.</span><cite>
Qi C, Gong J, Li J, et al. Claudin18.2‐specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189‐1198. doi: 10.1038/s41591-022-01800-8

</cite> [<a href="https://doi.org/10.1038/s41591-022-01800-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9205778/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35534566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Claudin18.2%E2%80%90specific%20CAR%20T%20cells%20in%20gastrointestinal%20cancers:%20phase%201%20trial%20interim%20results&amp;author=C%20Qi&amp;author=J%20Gong&amp;author=J%20Li&amp;volume=28&amp;issue=6&amp;publication_year=2022&amp;pages=1189-1198&amp;pmid=35534566&amp;doi=10.1038/s41591-022-01800-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0062">
<span class="label">62.</span><cite>
Yan Z, Zhang H, Cao J, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021;12:611366. doi: 10.3389/fimmu.2021.611366

</cite> [<a href="https://doi.org/10.3389/fimmu.2021.611366" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7940756/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33708205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Characteristics%20and%20risk%20factors%20of%20cytokine%20release%20syndrome%20in%20chimeric%20antigen%20receptor%20T%20cell%20treatment&amp;author=Z%20Yan&amp;author=H%20Zhang&amp;author=J%20Cao&amp;volume=12&amp;publication_year=2021&amp;pages=611366&amp;pmid=33708205&amp;doi=10.3389/fimmu.2021.611366&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0063">
<span class="label">63.</span><cite>
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T‐cell therapy ‐ assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47‐62. doi: 10.1038/nrclinonc.2017.148

</cite> [<a href="https://doi.org/10.1038/nrclinonc.2017.148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6733403/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28925994/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapy%20%E2%80%90%20assessment%20and%20management%20of%20toxicities&amp;author=SS%20Neelapu&amp;author=S%20Tummala&amp;author=P%20Kebriaei&amp;volume=15&amp;issue=1&amp;publication_year=2018&amp;pages=47-62&amp;pmid=28925994&amp;doi=10.1038/nrclinonc.2017.148&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0064">
<span class="label">64.</span><cite>
Hamida O, Karlsson F, Lundqvist A, Gerling M, Liu LL. Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden. OncoImmunology. 2024;13(1):2372875. doi: 10.1080/2162402x.2024.2372875

</cite> [<a href="https://doi.org/10.1080/2162402x.2024.2372875" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11225914/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38974986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=OncoImmunology&amp;title=Cytokine%20release%20syndrome%20after%20treatment%20with%20immune%20checkpoint%20inhibitors:%20an%20observational%20cohort%20study%20of%202672%20patients%20from%20Karolinska%20University%20Hospital%20in%20Sweden&amp;author=O%20Hamida&amp;author=F%20Karlsson&amp;author=A%20Lundqvist&amp;author=M%20Gerling&amp;author=LL%20Liu&amp;volume=13&amp;issue=1&amp;publication_year=2024&amp;pages=2372875&amp;pmid=38974986&amp;doi=10.1080/2162402x.2024.2372875&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0065">
<span class="label">65.</span><cite>
Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell‐related adverse events. J Immunother Cancer. 2020;8(2):e001511. doi: 10.1136/jitc-2020-001511

</cite> [<a href="https://doi.org/10.1136/jitc-2020-001511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7745688/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33335028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Society%20for%20Immunotherapy%20of%20Cancer%20(SITC)%20clinical%20practice%20guideline%20on%20immune%20effector%20cell%E2%80%90related%20adverse%20events&amp;author=MV%20Maus&amp;author=S%20Alexander&amp;author=MR%20Bishop&amp;volume=8&amp;issue=2&amp;publication_year=2020&amp;pages=e001511&amp;pmid=33335028&amp;doi=10.1136/jitc-2020-001511&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0066">
<span class="label">66.</span><cite>
Abufara AA, Alsahouri MI, Alsalah QA, Arafat H, Hammouri AG, Aqeel BA. Spontaneous tumor lysis syndrome in an adult with alveolar rhabdomyosarcoma: a challenging diagnosis. Oxf Med Case Reports. 2024;2024(5):omae043. doi: 10.1093/omcr/omae043

</cite> [<a href="https://doi.org/10.1093/omcr/omae043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11110853/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38784777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oxf%20Med%20Case%20Reports&amp;title=Spontaneous%20tumor%20lysis%20syndrome%20in%20an%20adult%20with%20alveolar%20rhabdomyosarcoma:%20a%20challenging%20diagnosis&amp;author=AA%20Abufara&amp;author=MI%20Alsahouri&amp;author=QA%20Alsalah&amp;author=H%20Arafat&amp;author=AG%20Hammouri&amp;volume=2024&amp;issue=5&amp;publication_year=2024&amp;pages=omae043&amp;pmid=38784777&amp;doi=10.1093/omcr/omae043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0067">
<span class="label">67.</span><cite>
Benitez‐Escobar EN, Galindes‐Casanova DA, Melo‐Burbano L, et al. First case report of tumor lysis syndrome after third line systemic therapy with gemcitabine and pazopanib in a patient with lower extremity soft tissue sarcoma. Chin Clin Oncol. 2023;12(45):China2023. doi: 10.21037/cco-22-111
</cite> [<a href="https://doi.org/10.21037/cco-22-111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37599513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chin%20Clin%20Oncol&amp;title=First%20case%20report%20of%20tumor%20lysis%20syndrome%20after%20third%20line%20systemic%20therapy%20with%20gemcitabine%20and%20pazopanib%20in%20a%20patient%20with%20lower%20extremity%20soft%20tissue%20sarcoma&amp;author=EN%20Benitez%E2%80%90Escobar&amp;author=DA%20Galindes%E2%80%90Casanova&amp;author=L%20Melo%E2%80%90Burbano&amp;volume=12&amp;issue=45&amp;publication_year=2023&amp;pages=China2023&amp;pmid=37599513&amp;doi=10.21037/cco-22-111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0068">
<span class="label">68.</span><cite>
Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T‐cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664‐679. doi: 10.1158/2159-8290.cd-16-0040

</cite> [<a href="https://doi.org/10.1158/2159-8290.cd-16-0040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5448406/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27076371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Identification%20of%20predictive%20biomarkers%20for%20cytokine%20release%20syndrome%20after%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapy%20for%20acute%20lymphoblastic%20leukemia&amp;author=DT%20Teachey&amp;author=SF%20Lacey&amp;author=PA%20Shaw&amp;volume=6&amp;issue=6&amp;publication_year=2016&amp;pages=664-679&amp;pmid=27076371&amp;doi=10.1158/2159-8290.cd-16-0040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0069">
<span class="label">69.</span><cite>
Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19‐28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi: 10.1126/scitranslmed.3008226
</cite> [<a href="https://doi.org/10.1126/scitranslmed.3008226" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4684949/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24553386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Transl%20Med&amp;title=Efficacy%20and%20toxicity%20management%20of%2019%E2%80%9028z%20CAR%20T%20cell%20therapy%20in%20B%20cell%20acute%20lymphoblastic%20leukemia&amp;author=ML%20Davila&amp;author=I%20Riviere&amp;author=X%20Wang&amp;volume=6&amp;issue=224&amp;publication_year=2014&amp;pages=224ra25&amp;pmid=24553386&amp;doi=10.1126/scitranslmed.3008226&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0070">
<span class="label">70.</span><cite>
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255‐2273. doi: 10.1056/nejmra2026131

</cite> [<a href="https://doi.org/10.1056/nejmra2026131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7727315/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33264547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Cytokine%20storm&amp;author=DC%20Fajgenbaum&amp;author=CH%20June&amp;volume=383&amp;issue=23&amp;publication_year=2020&amp;pages=2255-2273&amp;pmid=33264547&amp;doi=10.1056/nejmra2026131&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0071">
<span class="label">71.</span><cite>
Diorio C, Shaw PA, Pequignot E, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Adv. 2020;4(20):5174‐5183. doi: 10.1182/bloodadvances.2020002592

</cite> [<a href="https://doi.org/10.1182/bloodadvances.2020002592" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7594400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33095872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Diagnostic%20biomarkers%20to%20differentiate%20sepsis%20from%20cytokine%20release%20syndrome%20in%20critically%20ill%20children&amp;author=C%20Diorio&amp;author=PA%20Shaw&amp;author=E%20Pequignot&amp;volume=4&amp;issue=20&amp;publication_year=2020&amp;pages=5174-5183&amp;pmid=33095872&amp;doi=10.1182/bloodadvances.2020002592&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0072">
<span class="label">72.</span><cite>
National Cancer Institute
. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Online. National Institutes of Health. 2009. Accessed November 1, 2024. <a href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010‐06‐14_QuickReference_8.5x11.pdf</a>
</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Common%20Terminology%20Criteria%20for%20Adverse%20Events%20(CTCAE)%20Version%204.0%20Online&amp;publication_year=2009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0073">
<span class="label">73.</span><cite>
National Cancer Institute
. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 Online. National Institutes of Health. 2017. Accessed November 1, 2024. <a href="https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a>
</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Common%20Terminology%20Criteria%20for%20Adverse%20Events%20(CTCAE).%20Version%205.0%20Online&amp;publication_year=2017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0074">
<span class="label">74.</span><cite>
Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35. doi: 10.1186/s13045-018-0571-y

</cite> [<a href="https://doi.org/10.1186/s13045-018-0571-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5833070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29499750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Grading%20of%20cytokine%20release%20syndrome%20associated%20with%20the%20CAR%20T%20cell%20therapy%20tisagenlecleucel&amp;author=D%20Porter&amp;author=N%20Frey&amp;author=PA%20Wood&amp;author=Y%20Weng&amp;author=SA%20Grupp&amp;volume=11&amp;issue=1&amp;publication_year=2018&amp;pages=35&amp;pmid=29499750&amp;doi=10.1186/s13045-018-0571-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0075">
<span class="label">75.</span><cite>
Park JH, Rivière I, Gonen M, et al. Long‐term follow‐up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449‐459. doi: 10.1056/nejmoa1709919

</cite> [<a href="https://doi.org/10.1056/nejmoa1709919" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6637939/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29385376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Long%E2%80%90term%20follow%E2%80%90up%20of%20CD19%20CAR%20therapy%20in%20acute%20lymphoblastic%20leukemia&amp;author=JH%20Park&amp;author=I%20Rivi%C3%A8re&amp;author=M%20Gonen&amp;volume=378&amp;issue=5&amp;publication_year=2018&amp;pages=449-459&amp;pmid=29385376&amp;doi=10.1056/nejmoa1709919&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0076">
<span class="label">76.</span><cite>
Carvajal RD, Butler MO, Shoushtari AN, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022;28(11):2364‐2373. doi: 10.1038/s41591-022-02015-7

</cite> [<a href="https://doi.org/10.1038/s41591-022-02015-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9671803/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36229663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Clinical%20and%20molecular%20response%20to%20tebentafusp%20in%20previously%20treated%20patients%20with%20metastatic%20uveal%20melanoma:%20a%20phase%202%20trial&amp;author=RD%20Carvajal&amp;author=MO%20Butler&amp;author=AN%20Shoushtari&amp;volume=28&amp;issue=11&amp;publication_year=2022&amp;pages=2364-2373&amp;pmid=36229663&amp;doi=10.1038/s41591-022-02015-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0077">
<span class="label">77.</span><cite>
Sands JM, Champiat S, Hummel HD, et al. Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3‐targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer. Cancer. 2025;131(3):e35738. doi: 10.1002/cncr.35738

</cite> [<a href="https://doi.org/10.1002/cncr.35738" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11775405/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39876075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Practical%20management%20of%20adverse%20events%20in%20patients%20receiving%20tarlatamab,%20a%20delta%E2%80%90like%20ligand%203%E2%80%90targeted%20bispecific%20T%E2%80%90cell%20engager%20immunotherapy,%20for%20previously%20treated%20small%20cell%20lung%20cancer&amp;author=JM%20Sands&amp;author=S%20Champiat&amp;author=HD%20Hummel&amp;volume=131&amp;issue=3&amp;publication_year=2025&amp;pages=e35738&amp;pmid=39876075&amp;doi=10.1002/cncr.35738&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0078">
<span class="label">78.</span><cite>
Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T‐cell (CAR‐T) therapy for diffuse large B‐cell lymphoma. Am J Kidney Dis. 2020;76(1):63‐71. doi: 10.1053/j.ajkd.2019.10.011

</cite> [<a href="https://doi.org/10.1053/j.ajkd.2019.10.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7311244/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31973908/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Kidney%20Dis&amp;title=Acute%20kidney%20injury%20and%20electrolyte%20abnormalities%20after%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20(CAR%E2%80%90T)%20therapy%20for%20diffuse%20large%20B%E2%80%90cell%20lymphoma&amp;author=S%20Gupta&amp;author=H%20Seethapathy&amp;author=IA%20Strohbehn&amp;volume=76&amp;issue=1&amp;publication_year=2020&amp;pages=63-71&amp;pmid=31973908&amp;doi=10.1053/j.ajkd.2019.10.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0079">
<span class="label">79.</span><cite>
Vincendeau M, Joseph A, Thieblemont C, et al. Acute kidney injury after CAR‐T cell therapy: exploring clinical patterns, management, and outcomes. Clin Kidney J. 2024;17(6):sfae123. doi: 10.1093/ckj/sfae123

</cite> [<a href="https://doi.org/10.1093/ckj/sfae123" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11195623/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38915438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Kidney%20J&amp;title=Acute%20kidney%20injury%20after%20CAR%E2%80%90T%20cell%20therapy:%20exploring%20clinical%20patterns,%20management,%20and%20outcomes&amp;author=M%20Vincendeau&amp;author=A%20Joseph&amp;author=C%20Thieblemont&amp;volume=17&amp;issue=6&amp;publication_year=2024&amp;pages=sfae123&amp;pmid=38915438&amp;doi=10.1093/ckj/sfae123&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0080">
<span class="label">80.</span><cite>
Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol. 2018;13(5):796‐798. doi: 10.2215/cjn.12871117

</cite> [<a href="https://doi.org/10.2215/cjn.12871117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5969488/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29523675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20J%20Am%20Soc%20Nephrol&amp;title=Chimeric%20antigen%20receptor%20T%20cell%20therapy%20and%20the%20kidney:%20what%20the%20nephrologist%20needs%20to%20know&amp;author=KD%20Jhaveri&amp;author=MH%20Rosner&amp;volume=13&amp;issue=5&amp;publication_year=2018&amp;pages=796-798&amp;pmid=29523675&amp;doi=10.2215/cjn.12871117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0081">
<span class="label">81.</span><cite>
Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune‐related adverse events in patients treated with chimeric antigen receptor T‐cell therapy: ASCO Guideline. J Clin Oncol. 2021;39(35):3978‐3992. doi: 10.1200/jco.21.01992

</cite> [<a href="https://doi.org/10.1200/jco.21.01992" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34724386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Management%20of%20immune%E2%80%90related%20adverse%20events%20in%20patients%20treated%20with%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapy:%20ASCO%20Guideline&amp;author=BD%20Santomasso&amp;author=LJ%20Nastoupil&amp;author=S%20Adkins&amp;volume=39&amp;issue=35&amp;publication_year=2021&amp;pages=3978-3992&amp;pmid=34724386&amp;doi=10.1200/jco.21.01992&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0082">
<span class="label">82.</span><cite>
Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23(8):943‐947. doi: 10.1634/theoncologist.2018-0028

</cite> [<a href="https://doi.org/10.1634/theoncologist.2018-0028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6156173/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29622697/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=FDA%20approval%20summary:%20tocilizumab%20for%20treatment%20of%20chimeric%20antigen%20receptor%20T%20cell%E2%80%90induced%20severe%20or%20life%E2%80%90threatening%20cytokine%20release%20syndrome&amp;author=RQ%20Le&amp;author=L%20Li&amp;author=W%20Yuan&amp;volume=23&amp;issue=8&amp;publication_year=2018&amp;pages=943-947&amp;pmid=29622697&amp;doi=10.1634/theoncologist.2018-0028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0083">
<span class="label">83.</span><cite>
Reagan PM, Neelapu SS. How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T‐cell therapies. J Clin Oncol. 2021;39(5):456‐466. doi: 10.1200/jco.20.01616

</cite> [<a href="https://doi.org/10.1200/jco.20.01616" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33434058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=How%20I%20manage:%20pathophysiology%20and%20management%20of%20toxicity%20of%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapies&amp;author=PM%20Reagan&amp;author=SS%20Neelapu&amp;volume=39&amp;issue=5&amp;publication_year=2021&amp;pages=456-466&amp;pmid=33434058&amp;doi=10.1200/jco.20.01616&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0084">
<span class="label">84.</span><cite>
Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T‐cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149‐2158. doi: 10.1182/blood.2019001463

</cite> [<a href="https://doi.org/10.1182/blood.2019001463" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6908832/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31697826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Preemptive%20mitigation%20of%20CD19%20CAR%20T%E2%80%90cell%20cytokine%20release%20syndrome%20without%20attenuation%20of%20antileukemic%20efficacy&amp;author=RA%20Gardner&amp;author=F%20Ceppi&amp;author=J%20Rivers&amp;volume=134&amp;issue=24&amp;publication_year=2019&amp;pages=2149-2158&amp;pmid=31697826&amp;doi=10.1182/blood.2019001463&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0085">
<span class="label">85.</span><cite>
Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell‐associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501‐521. doi: 10.1038/s41571-024-00903-0

</cite> [<a href="https://doi.org/10.1038/s41571-024-00903-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11529341/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38769449/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Current%20understanding%20and%20management%20of%20CAR%20T%20cell%E2%80%90associated%20toxicities&amp;author=JN%20Brudno&amp;author=JN%20Kochenderfer&amp;volume=21&amp;issue=7&amp;publication_year=2024&amp;pages=501-521&amp;pmid=38769449&amp;doi=10.1038/s41571-024-00903-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0086">
<span class="label">86.</span><cite>
Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose‐finding study of repetitive treatment with the humanized anti‐interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30(7):1426‐1435.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/12858437/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Rheumatol&amp;title=Toxicity,%20pharmacokinetics,%20and%20dose%E2%80%90finding%20study%20of%20repetitive%20treatment%20with%20the%20humanized%20anti%E2%80%90interleukin%206%20receptor%20antibody%20MRA%20in%20rheumatoid%20arthritis.%20Phase%20I/II%20clinical%20study&amp;author=N%20Nishimoto&amp;author=K%20Yoshizaki&amp;author=K%20Maeda&amp;volume=30&amp;issue=7&amp;publication_year=2003&amp;pages=1426-1435&amp;pmid=12858437&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0087">
<span class="label">87.</span><cite>
Song SN, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2015;11(2):307‐316. doi: 10.1517/17425255.2015.992779

</cite> [<a href="https://doi.org/10.1517/17425255.2015.992779" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25491492/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Drug%20Metab%20Toxicol&amp;title=Tocilizumab%20for%20treating%20rheumatoid%20arthritis:%20an%20evaluation%20of%20pharmacokinetics/pharmacodynamics%20and%20clinical%20efficacy&amp;author=SN%20Song&amp;author=K%20Yoshizaki&amp;volume=11&amp;issue=2&amp;publication_year=2015&amp;pages=307-316&amp;pmid=25491492&amp;doi=10.1517/17425255.2015.992779&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0088">
<span class="label">88.</span><cite>
Li C, Tang X, Zhou Z, et al. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial. Clin Rheumatol. 2024;43(11):3457‐3467. doi: 10.1007/s10067-024-07126-9

</cite> [<a href="https://doi.org/10.1007/s10067-024-07126-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11489204/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39279018/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Rheumatol&amp;title=Efficacy%20and%20safety%20of%20tocilizumab%20in%20Chinese%20patients%20with%20systemic%20juvenile%20idiopathic%20arthritis:%20a%20multicentre%20phase%20IV%20trial&amp;author=C%20Li&amp;author=X%20Tang&amp;author=Z%20Zhou&amp;volume=43&amp;issue=11&amp;publication_year=2024&amp;pages=3457-3467&amp;pmid=39279018&amp;doi=10.1007/s10067-024-07126-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0089">
<span class="label">89.</span><cite>
Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456‐464. doi: 10.1136/annrheumdis-2018-214367

</cite> [<a href="https://doi.org/10.1136/annrheumdis-2018-214367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30679153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Rheum%20Dis&amp;title=Risk%20of%20serious%20infections%20in%20tocilizumab%20versus%20other%20biologic%20drugs%20in%20patients%20with%20rheumatoid%20arthritis:%20a%20multidatabase%20cohort%20study&amp;author=A%20Pawar&amp;author=RJ%20Desai&amp;author=DH%20Solomon&amp;volume=78&amp;issue=4&amp;publication_year=2019&amp;pages=456-464&amp;pmid=30679153&amp;doi=10.1136/annrheumdis-2018-214367&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0090">
<span class="label">90.</span><cite>
Hunter BD, Jacobson CA. CAR T‐cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111(7):646‐654. doi: 10.1093/jnci/djz017

</cite> [<a href="https://doi.org/10.1093/jnci/djz017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30753567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=CAR%20T%E2%80%90cell%20associated%20neurotoxicity:%20mechanisms,%20clinicopathologic%20correlates,%20and%20future%20directions&amp;author=BD%20Hunter&amp;author=CA%20Jacobson&amp;volume=111&amp;issue=7&amp;publication_year=2019&amp;pages=646-654&amp;pmid=30753567&amp;doi=10.1093/jnci/djz017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0091">
<span class="label">91.</span><cite>
Nellan A, McCully CML, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018;132(6):662‐666. United States 2018. doi: 10.1182/blood-2018-05-846428

</cite> [<a href="https://doi.org/10.1182/blood-2018-05-846428" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6086204/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29954750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Improved%20CNS%20exposure%20to%20tocilizumab%20after%20cerebrospinal%20fluid%20compared%20to%20intravenous%20administration%20in%20rhesus%20macaques&amp;author=A%20Nellan&amp;author=CML%20McCully&amp;author=R%20Cruz%20Garcia&amp;volume=132&amp;issue=6&amp;publication_year=2018&amp;pages=662-666&amp;pmid=29954750&amp;doi=10.1182/blood-2018-05-846428&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0092">
<span class="label">92.</span><cite>
Daoudlarian D, Segot A, Latifyan S, et al. Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy. Ann Oncol. 2025;36(4):444‐459. doi: 10.1016/j.annonc.2024.12.004

</cite> [<a href="https://doi.org/10.1016/j.annonc.2024.12.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39701282/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Tocilizumab%20and%20immune%20signatures%20for%20targeted%20management%20of%20cytokine%20release%20syndrome%20in%20immune%20checkpoint%20therapy&amp;author=D%20Daoudlarian&amp;author=A%20Segot&amp;author=S%20Latifyan&amp;volume=36&amp;issue=4&amp;publication_year=2025&amp;pages=444-459&amp;pmid=39701282&amp;doi=10.1016/j.annonc.2024.12.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0093">
<span class="label">93.</span><cite>
Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2022;33(12):1217‐1238. doi: 10.1016/j.annonc.2022.10.001

</cite> [<a href="https://doi.org/10.1016/j.annonc.2022.10.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36270461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Management%20of%20toxicities%20from%20immunotherapy:%20ESMO%20clinical%20practice%20guideline%20for%20diagnosis,%20treatment%20and%20follow%E2%80%90up&amp;author=J%20Haanen&amp;author=M%20Obeid&amp;author=L%20Spain&amp;volume=33&amp;issue=12&amp;publication_year=2022&amp;pages=1217-1238&amp;pmid=36270461&amp;doi=10.1016/j.annonc.2022.10.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0094">
<span class="label">94.</span><cite>
Brahmer JR, Abu‐Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor‐related adverse events. J Immunother Cancer. 2021;9(6):e002435. doi: 10.1136/jitc-2021-002435

</cite> [<a href="https://doi.org/10.1136/jitc-2021-002435" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8237720/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34172516/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Society%20for%20Immunotherapy%20of%20Cancer%20(SITC)%20clinical%20practice%20guideline%20on%20immune%20checkpoint%20inhibitor%E2%80%90related%20adverse%20events&amp;author=JR%20Brahmer&amp;author=H%20Abu%E2%80%90Sbeih&amp;author=PA%20Ascierto&amp;volume=9&amp;issue=6&amp;publication_year=2021&amp;pages=e002435&amp;pmid=34172516&amp;doi=10.1136/jitc-2021-002435&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0095">
<span class="label">95.</span><cite>
Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T‐cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259‐275. doi: 10.1016/j.annonc.2021.12.003

</cite> [<a href="https://doi.org/10.1016/j.annonc.2021.12.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34923107/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Management%20of%20adults%20and%20children%20receiving%20CAR%20T%E2%80%90cell%20therapy:%202021%20best%20practice%20recommendations%20of%20the%20European%20Society%20for%20Blood%20and%20Marrow%20Transplantation%20(EBMT)%20and%20the%20Joint%20Accreditation%20Committee%20of%20ISCT%20and%20EBMT%20(JACIE)%20and%20the%20European%20Haematology%20Association%20(EHA)&amp;author=PJ%20Hayden&amp;author=C%20Roddie&amp;author=P%20Bader&amp;volume=33&amp;issue=3&amp;publication_year=2022&amp;pages=259-275&amp;pmid=34923107&amp;doi=10.1016/j.annonc.2021.12.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0096">
<span class="label">96.</span><cite>
National Comprehensive Cancer Network
. Management of Immunotherapy Related Toxicities. Version 02. 2024. Accessed November 4, 2024. <a href="https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf</a>
</cite>
</li>
<li id="cncr70069-bib-0097">
<span class="label">97.</span><cite>
Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid‐induced adverse events in adults: frequency, screening and prevention. Drug Saf. 2007;30(10):861‐881. doi: 10.2165/00002018-200730100-00005

</cite> [<a href="https://doi.org/10.2165/00002018-200730100-00005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17867724/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Saf&amp;title=Corticosteroid%E2%80%90induced%20adverse%20events%20in%20adults:%20frequency,%20screening%20and%20prevention&amp;author=L%20Fardet&amp;author=A%20Kassar&amp;author=J%20Cabane&amp;author=A%20Flahault&amp;volume=30&amp;issue=10&amp;publication_year=2007&amp;pages=861-881&amp;pmid=17867724&amp;doi=10.2165/00002018-200730100-00005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0098">
<span class="label">98.</span><cite>
Brentjens RJ, Davila ML, Riviere I, et al. CD19‐targeted T cells rapidly induce molecular remissions in adults with chemotherapy‐refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38. doi: 10.1126/scitranslmed.3005930
</cite> [<a href="https://doi.org/10.1126/scitranslmed.3005930" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3742551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23515080/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Transl%20Med&amp;title=CD19%E2%80%90targeted%20T%20cells%20rapidly%20induce%20molecular%20remissions%20in%20adults%20with%20chemotherapy%E2%80%90refractory%20acute%20lymphoblastic%20leukemia&amp;author=RJ%20Brentjens&amp;author=ML%20Davila&amp;author=I%20Riviere&amp;volume=5&amp;issue=177&amp;publication_year=2013&amp;pages=177ra38&amp;pmid=23515080&amp;doi=10.1126/scitranslmed.3005930&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0099">
<span class="label">99.</span><cite>
Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi: 10.1126/scitranslmed.3002842
</cite> [<a href="https://doi.org/10.1126/scitranslmed.3002842" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3393096/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21832238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Transl%20Med&amp;title=T%20cells%20with%20chimeric%20antigen%20receptors%20have%20potent%20antitumor%20effects%20and%20can%20establish%20memory%20in%20patients%20with%20advanced%20leukemia&amp;author=M%20Kalos&amp;author=BL%20Levine&amp;author=DL%20Porter&amp;volume=3&amp;issue=95&amp;publication_year=2011&amp;pages=95ra73&amp;pmid=21832238&amp;doi=10.1126/scitranslmed.3002842&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0100">
<span class="label">100.</span><cite>
Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non‐trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095‐3106. doi: 10.1200/jco.19.02103

</cite> [<a href="https://doi.org/10.1200/jco.19.02103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7499617/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32667831/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Axicabtagene%20ciloleucel%20in%20the%20non%E2%80%90trial%20setting:%20outcomes%20and%20correlates%20of%20response,%20resistance,%20and%20toxicity&amp;author=CA%20Jacobson&amp;author=BD%20Hunter&amp;author=R%20Redd&amp;volume=38&amp;issue=27&amp;publication_year=2020&amp;pages=3095-3106&amp;pmid=32667831&amp;doi=10.1200/jco.19.02103&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0101">
<span class="label">101.</span><cite>
Wang M, Munoz J, Goy A, et al. KTE‐X19 CAR T‐cell therapy in relapsed or refractory mantle‐cell lymphoma. N Engl J Med. 2020;382(14):1331‐1342. doi: 10.1056/nejmoa1914347

</cite> [<a href="https://doi.org/10.1056/nejmoa1914347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7731441/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32242358/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=KTE%E2%80%90X19%20CAR%20T%E2%80%90cell%20therapy%20in%20relapsed%20or%20refractory%20mantle%E2%80%90cell%20lymphoma&amp;author=M%20Wang&amp;author=J%20Munoz&amp;author=A%20Goy&amp;volume=382&amp;issue=14&amp;publication_year=2020&amp;pages=1331-1342&amp;pmid=32242358&amp;doi=10.1056/nejmoa1914347&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0102">
<span class="label">102.</span><cite>
Muth A, Philipp N, Marcinek A, et al. Beyond mitigating immune‐related adverse events: glucocorticoids ameliorate bispecific antibody‐mediated T‐cell exhaustion in vitro. Blood. 2023;142(suppl 1):5389. doi: 10.1182/blood-2023-174258
</cite> [<a href="https://doi.org/10.1182/blood-2023-174258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Beyond%20mitigating%20immune%E2%80%90related%20adverse%20events:%20glucocorticoids%20ameliorate%20bispecific%20antibody%E2%80%90mediated%20T%E2%80%90cell%20exhaustion%20in%20vitro&amp;author=A%20Muth&amp;author=N%20Philipp&amp;author=A%20Marcinek&amp;volume=142&amp;issue=suppl%201&amp;publication_year=2023&amp;pages=5389&amp;doi=10.1182/blood-2023-174258&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0103">
<span class="label">103.</span><cite>
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B‐cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839‐852. doi: 10.1016/s0140-6736(20)31366-0

</cite> [<a href="https://doi.org/10.1016/s0140-6736(20)31366-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32888407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Lisocabtagene%20maraleucel%20for%20patients%20with%20relapsed%20or%20refractory%20large%20B%E2%80%90cell%20lymphomas%20(TRANSCEND%20NHL%20001):%20a%20multicentre%20seamless%20design%20study&amp;author=JS%20Abramson&amp;author=ML%20Palomba&amp;author=LI%20Gordon&amp;volume=396&amp;issue=10254&amp;publication_year=2020&amp;pages=839-852&amp;pmid=32888407&amp;doi=10.1016/s0140-6736(20)31366-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0104">
<span class="label">104.</span><cite>
Bajwa A, Zhao Q, Geer MJ, et al. Siltuximab for chimeric antigen receptor T‐cell therapy related CRS and ICANS ‐ a multicenter retrospective analysis. Blood Adv. 2024;9(1):170‐175. doi: 10.1182/bloodadvances.2024013688
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2024013688" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11788129/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39437770/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Siltuximab%20for%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapy%20related%20CRS%20and%20ICANS%20%E2%80%90%20a%20multicenter%20retrospective%20analysis&amp;author=A%20Bajwa&amp;author=Q%20Zhao&amp;author=MJ%20Geer&amp;volume=9&amp;issue=1&amp;publication_year=2024&amp;pages=170-175&amp;pmid=39437770&amp;doi=10.1182/bloodadvances.2024013688&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0105">
<span class="label">105.</span><cite>
Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to mitigate CAR T‐cell therapy‐associated toxicity in large B‐cell lymphoma. Blood Adv. 2020;4(13):3123‐3127. doi: 10.1182/bloodadvances.2020002328

</cite> [<a href="https://doi.org/10.1182/bloodadvances.2020002328" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7362369/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32645136/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Clinical%20efficacy%20of%20anakinra%20to%20mitigate%20CAR%20T%E2%80%90cell%20therapy%E2%80%90associated%20toxicity%20in%20large%20B%E2%80%90cell%20lymphoma&amp;author=P%20Strati&amp;author=S%20Ahmed&amp;author=P%20Kebriaei&amp;volume=4&amp;issue=13&amp;publication_year=2020&amp;pages=3123-3127&amp;pmid=32645136&amp;doi=10.1182/bloodadvances.2020002328&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0106">
<span class="label">106.</span><cite>
Pan J, Deng B, Ling Z, et al. Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy. J Cell Mol Med. 2021;25(2):1089‐1099. doi: 10.1111/jcmm.16176

</cite> [<a href="https://doi.org/10.1111/jcmm.16176" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7812291/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33314568/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cell%20Mol%20Med&amp;title=Ruxolitinib%20mitigates%20steroid%E2%80%90refractory%20CRS%20during%20CAR%20T%20therapy&amp;author=J%20Pan&amp;author=B%20Deng&amp;author=Z%20Ling&amp;volume=25&amp;issue=2&amp;publication_year=2021&amp;pages=1089-1099&amp;pmid=33314568&amp;doi=10.1111/jcmm.16176&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0107">
<span class="label">107.</span><cite>
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321‐3330. doi: 10.1182/blood-2016-04-703751

</cite> [<a href="https://doi.org/10.1182/blood-2016-04-703751" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4929924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27207799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Toxicities%20of%20chimeric%20antigen%20receptor%20T%20cells:%20recognition%20and%20management&amp;author=JN%20Brudno&amp;author=JN%20Kochenderfer&amp;volume=127&amp;issue=26&amp;publication_year=2016&amp;pages=3321-3330&amp;pmid=27207799&amp;doi=10.1182/blood-2016-04-703751&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0108">
<span class="label">108.</span><cite>
Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR‐T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Investig. 2016;126(6):2123‐2138. doi: 10.1172/jci85309

</cite> [<a href="https://doi.org/10.1172/jci85309" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4887159/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27111235/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Investig&amp;title=CD19%20CAR%E2%80%90T%20cells%20of%20defined%20CD4+:CD8+%20composition%20in%20adult%20B%20cell%20ALL%20patients&amp;author=CJ%20Turtle&amp;author=LA%20Hanafi&amp;author=C%20Berger&amp;volume=126&amp;issue=6&amp;publication_year=2016&amp;pages=2123-2138&amp;pmid=27111235&amp;doi=10.1172/jci85309&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0109">
<span class="label">109.</span><cite>
Iwata Y, Sasaki M, Harada A, et al. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T‐cell redirecting bispecific antibody ERY974 for cancer immunotherapy. Toxicol Appl Pharmacol. 2019;379:114657. doi: 10.1016/j.taap.2019.114657

</cite> [<a href="https://doi.org/10.1016/j.taap.2019.114657" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31326447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Toxicol%20Appl%20Pharmacol&amp;title=Daily%20ascending%20dosing%20in%20cynomolgus%20monkeys%20to%20mitigate%20cytokine%20release%20syndrome%20induced%20by%20ERY22,%20surrogate%20for%20T%E2%80%90cell%20redirecting%20bispecific%20antibody%20ERY974%20for%20cancer%20immunotherapy&amp;author=Y%20Iwata&amp;author=M%20Sasaki&amp;author=A%20Harada&amp;volume=379&amp;publication_year=2019&amp;pages=114657&amp;pmid=31326447&amp;doi=10.1016/j.taap.2019.114657&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0110">
<span class="label">110.</span><cite>
Deppisch N, Ruf P, Eissler N, et al. Efficacy and tolerability of a GD2‐directed trifunctional bispecific antibody in a preclinical model: subcutaneous administration is superior to intravenous delivery. Mol Cancer Therapeut. 2015;14(8):1877‐1883. doi: 10.1158/1535-7163.mct-15-0156
</cite> [<a href="https://doi.org/10.1158/1535-7163.mct-15-0156" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26063765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Therapeut&amp;title=Efficacy%20and%20tolerability%20of%20a%20GD2%E2%80%90directed%20trifunctional%20bispecific%20antibody%20in%20a%20preclinical%20model:%20subcutaneous%20administration%20is%20superior%20to%20intravenous%20delivery&amp;author=N%20Deppisch&amp;author=P%20Ruf&amp;author=N%20Eissler&amp;volume=14&amp;issue=8&amp;publication_year=2015&amp;pages=1877-1883&amp;pmid=26063765&amp;doi=10.1158/1535-7163.mct-15-0156&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0111">
<span class="label">111.</span><cite>
Frigault MJ, Maziarz RT, Park JH, et al. Itacitinib for the prevention of immune effector cell therapy‐associated cytokine release syndrome: results from the phase 2 INCB 39110‐211 placebo‐controlled randomized cohort. Blood. 2023;142(suppl 1):356. doi: 10.1182/blood-2023-180205
</cite> [<a href="https://doi.org/10.1182/blood-2023-180205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Itacitinib%20for%20the%20prevention%20of%20immune%20effector%20cell%20therapy%E2%80%90associated%20cytokine%20release%20syndrome:%20results%20from%20the%20phase%202%20INCB%2039110%E2%80%90211%20placebo%E2%80%90controlled%20randomized%20cohort&amp;author=MJ%20Frigault&amp;author=RT%20Maziarz&amp;author=JH%20Park&amp;volume=142&amp;issue=suppl%201&amp;publication_year=2023&amp;pages=356&amp;doi=10.1182/blood-2023-180205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0112">
<span class="label">112.</span><cite>
Zhang L, Wang S, Xu J, et al. Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy. Exp Hematol Oncol. 2021;10(16):England2021. doi: 10.1186/s40164-021-00209-2
</cite> [<a href="https://doi.org/10.1186/s40164-021-00209-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7893957/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33608054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Hematol%20Oncol&amp;title=Etanercept%20as%20a%20new%20therapeutic%20option%20for%20cytokine%20release%20syndrome%20following%20chimeric%20antigen%20receptor%20T%20cell%20therapy&amp;author=L%20Zhang&amp;author=S%20Wang&amp;author=J%20Xu&amp;volume=10&amp;issue=16&amp;publication_year=2021&amp;pages=England2021&amp;pmid=33608054&amp;doi=10.1186/s40164-021-00209-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0113">
<span class="label">113.</span><cite>
Leclercq G, Haegel H, Schneider A, et al. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J Immunother Cancer. 2021;9(7):e002582. doi: 10.1136/jitc-2021-002582

</cite> [<a href="https://doi.org/10.1136/jitc-2021-002582" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8323395/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34326166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Src/lck%20inhibitor%20dasatinib%20reversibly%20switches%20off%20cytokine%20release%20and%20T%20cell%20cytotoxicity%20following%20stimulation%20with%20T%20cell%20bispecific%20antibodies&amp;author=G%20Leclercq&amp;author=H%20Haegel&amp;author=A%20Schneider&amp;volume=9&amp;issue=7&amp;publication_year=2021&amp;pages=e002582&amp;pmid=34326166&amp;doi=10.1136/jitc-2021-002582&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0114">
<span class="label">114.</span><cite>
Baur K, Heim D, Beerlage A, et al. Dasatinib for treatment of CAR T‐cell therapy‐related complications. J Immunother Cancer. 2022;10(12):e005956. doi: 10.1136/jitc-2022-005956

</cite> [<a href="https://doi.org/10.1136/jitc-2022-005956" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9717332/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36455991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Dasatinib%20for%20treatment%20of%20CAR%20T%E2%80%90cell%20therapy%E2%80%90related%20complications&amp;author=K%20Baur&amp;author=D%20Heim&amp;author=A%20Beerlage&amp;volume=10&amp;issue=12&amp;publication_year=2022&amp;pages=e005956&amp;pmid=36455991&amp;doi=10.1136/jitc-2022-005956&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0115">
<span class="label">115.</span><cite>
Xiao X, He X, Li Q, et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor‐T cell infusion: a case report. Clin Cancer Res. 2019;25(1):29‐34. doi: 10.1158/1078-0432.ccr-18-1379

</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-18-1379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30322878/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Plasma%20exchange%20can%20be%20an%20alternative%20therapeutic%20modality%20for%20severe%20cytokine%20release%20syndrome%20after%20chimeric%20antigen%20receptor%E2%80%90T%20cell%20infusion:%20a%20case%20report&amp;author=X%20Xiao&amp;author=X%20He&amp;author=Q%20Li&amp;volume=25&amp;issue=1&amp;publication_year=2019&amp;pages=29-34&amp;pmid=30322878&amp;doi=10.1158/1078-0432.ccr-18-1379&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0116">
<span class="label">116.</span><cite>
Pu Y, Zhao Y, Qi Y, et al. Multi‐centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab‐refractory cytokine release syndrome following CAR‐T therapy. Int Immunopharmacol. 2024;130:111761. doi: 10.1016/j.intimp.2024.111761

</cite> [<a href="https://doi.org/10.1016/j.intimp.2024.111761" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38422769/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20Immunopharmacol&amp;title=Multi%E2%80%90centers%20experience%20using%20therapeutic%20plasma%20exchange%20for%20corticosteroid/tocilizumab%E2%80%90refractory%20cytokine%20release%20syndrome%20following%20CAR%E2%80%90T%20therapy&amp;author=Y%20Pu&amp;author=Y%20Zhao&amp;author=Y%20Qi&amp;volume=130&amp;publication_year=2024&amp;pages=111761&amp;pmid=38422769&amp;doi=10.1016/j.intimp.2024.111761&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0117">
<span class="label">117.</span><cite>
Porosnicu TM, Sirbu IO, Oancea C, et al. The impact of therapeutic plasma exchange on inflammatory markers and acute phase reactants in patients with severe SARS‐CoV‐2 infection. Medicina (Kaunas). 2023;59(5):867. doi: 10.3390/medicina59050867

</cite> [<a href="https://doi.org/10.3390/medicina59050867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10221344/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37241099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicina%20(Kaunas)&amp;title=The%20impact%20of%20therapeutic%20plasma%20exchange%20on%20inflammatory%20markers%20and%20acute%20phase%20reactants%20in%20patients%20with%20severe%20SARS%E2%80%90CoV%E2%80%902%20infection&amp;author=TM%20Porosnicu&amp;author=IO%20Sirbu&amp;author=C%20Oancea&amp;volume=59&amp;issue=5&amp;publication_year=2023&amp;pages=867&amp;pmid=37241099&amp;doi=10.3390/medicina59050867&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0118">
<span class="label">118.</span><cite>
Zheng X, Zhang S, Wu H, et al. Plasma exchange as an effective treatment for cytokine release syndrome following T cell receptor‐engineered T cell immunotherapy: a case report. Oncol Lett. 2024;28(6):607. doi: 10.3892/ol.2024.14740

</cite> [<a href="https://doi.org/10.3892/ol.2024.14740" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11526442/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39483965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncol%20Lett&amp;title=Plasma%20exchange%20as%20an%20effective%20treatment%20for%20cytokine%20release%20syndrome%20following%20T%20cell%20receptor%E2%80%90engineered%20T%20cell%20immunotherapy:%20a%20case%20report&amp;author=X%20Zheng&amp;author=S%20Zhang&amp;author=H%20Wu&amp;volume=28&amp;issue=6&amp;publication_year=2024&amp;pages=607&amp;pmid=39483965&amp;doi=10.3892/ol.2024.14740&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0119">
<span class="label">119.</span><cite>
Balagopal S, Sasaki K, Kaur P, Nikolaidi M, Ishihara J. Emerging approaches for preventing cytokine release syndrome in CAR‐T cell therapy. J Mater Chem B. 2022;10(37):7491‐7511. doi: 10.1039/d2tb00592a

</cite> [<a href="https://doi.org/10.1039/d2tb00592a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9518648/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35912720/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mater%20Chem%20B&amp;title=Emerging%20approaches%20for%20preventing%20cytokine%20release%20syndrome%20in%20CAR%E2%80%90T%20cell%20therapy&amp;author=S%20Balagopal&amp;author=K%20Sasaki&amp;author=P%20Kaur&amp;author=M%20Nikolaidi&amp;author=J%20Ishihara&amp;volume=10&amp;issue=37&amp;publication_year=2022&amp;pages=7491-7511&amp;pmid=35912720&amp;doi=10.1039/d2tb00592a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0120">
<span class="label">120.</span><cite>
Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus‐thymidine kinase/ganciclovir cancer gene therapy: role of gap‐junctional intercellular communication. Cancer Res. 2000;60(15):3989‐3999.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10945596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Bystander%20effect%20in%20herpes%20simplex%20virus%E2%80%90thymidine%20kinase/ganciclovir%20cancer%20gene%20therapy:%20role%20of%20gap%E2%80%90junctional%20intercellular%20communication&amp;author=M%20Mesnil&amp;author=H%20Yamasaki&amp;volume=60&amp;issue=15&amp;publication_year=2000&amp;pages=3989-3999&amp;pmid=10945596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cncr70069-bib-0121">
<span class="label">121.</span><cite>
Diaconu I, Ballard B, Zhang M, et al. Inducible caspase‐9 selectively modulates the toxicities of CD19‐specific chimeric antigen receptor‐modified T cells. Mol Ther. 2017;25(3):580‐592. doi: 10.1016/j.ymthe.2017.01.011

</cite> [<a href="https://doi.org/10.1016/j.ymthe.2017.01.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5363196/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28187946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther&amp;title=Inducible%20caspase%E2%80%909%20selectively%20modulates%20the%20toxicities%20of%20CD19%E2%80%90specific%20chimeric%20antigen%20receptor%E2%80%90modified%20T%20cells&amp;author=I%20Diaconu&amp;author=B%20Ballard&amp;author=M%20Zhang&amp;volume=25&amp;issue=3&amp;publication_year=2017&amp;pages=580-592&amp;pmid=28187946&amp;doi=10.1016/j.ymthe.2017.01.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>This is a review article. Relevant sources are referenced in article.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cancer are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/cncr.70069"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/CNCR-131-e70069.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.4 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374489/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374489/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374489%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374489/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374489/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374489/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40847830/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374489/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40847830/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374489/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374489/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="o7snIdkQewiZjVlLPkyHzvYUd63N2PvA0K0O6Aw0USKo6NICkJxY16lXdnRWAAhX">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
